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Heme is an essential molecule for all aerobic life. It acts as a co-factor for a wide variety 
of different proteins involved in functions as diverse as oxygen transport, energy 
generation and catalysis. Free or unbound heme also has a less well understood role as 
a signalling molecule, involved in transcriptional control, protein degradation, circadian 
regulation and cellular redox homeostasis. However, free heme is also cytotoxic through 
its pro-oxidant activity and its ability to trigger inflammatory cascades. Investigations 
into the role of heme in physiological processes and disease have been hampered by the 
lack of specific heme sensors that can be used in live cells to distinguish the low 
concentrations of the free heme pool from the protein-bound fraction. In this thesis, 
potential heme sensors have been designed and synthesised based on the amino acid 
sequences of heme-binding regions in the proteins Bach1 and hemopexin. Synthetic 
peptides with a CP motif derived from Bach1 were found to bind heme in a 1:1 ratio with 
low micromolar affinity by UV-vis titrations. One such peptide was modified to 
incorporate a 7-azatryptophan residue in place of tryptophan and quenching of the red-
shifted fluorescence was shown to be proportional to hemin concentration. This lead 
Bach1-derived peptide was used to measure heme levels in skin cell lysates and 
confirmed an increase in heme levels after treatment of cells with hemin or UVA 
irradiation. Further developments of this prototype sensor molecule have also been 
explored including the incorporation of a cell penetrating peptide sequence that 
improved uptake of the peptide by human skin cells in vitro. Conjugation of a second 
independent fluorophore to the heme-binding peptide was also investigated to prepare 
it for use in live cells, but this reduced the fluorescence of 7-azatryptophan, indicating 
that further optimisation of the fluorophore combination will ultimately be required. In 
summary, these studies provide the basis for the development of flexible peptide-based 
heme sensors that can be used to monitor heme levels in biological media. Further 
development should provide effective tools for probing the diverse physiological 
functions of heme, as well as aiding our understanding of how proteins such as Bach1 
regulate the transcription of genes associated with heme degradation.  
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Heme (iron protoporphyrin IX) is a tetrapyrrole ring with a ferrous (Fe2+) iron coordinated 
at the centre. It is readily oxidised to the ferric iron (Fe3+) and the residual positive charge 
on the iron may be neutralised by a chloride iron forming hemin with a pentacoordinate 
square pyramidal structure.  
Heme is an essential molecule for all aerobic organisms and is a prosthetic group for a 
large variety of proteins. Its iron atom gives heme the ability to carry out oxido-reduction 
reactions, and this ability is responsible and crucial for the biochemical actions of these 
proteins (Smith 2009). In the globin proteins, heme transports and stores oxygen 
(Baldwin and Chothia 1979). In cytochromes, heme transports electrons and generates 
energy (Babcock and Wikström 1992). In a wide variety of enzymes such as catalases, 
peroxidases, cyclooxygenase and nitric-oxide synthase, heme activates oxygen or H2O2 
to oxidise substrates (Poulos 2014). 
 
While acting as a protein cofactor was the traditionally accepted function of heme in 
eukaryotes, it is now understood that free or labile heme is also an important cellular 
signalling molecule (Chiabrando et al. 2014). In such a role, heme can influence gene 
transcription, protein degradation (Ponka 1999), miRNA processing (Faller et al. 2007), 
circadian regulation (Yin et al. 2007), the immune response (Soares and Bozza 2016) and 
cellular redox homeostasis (Girvan and Munro 2013). 
 
There are several natural types of heme which contain the same porphyrin core but 
have different side chains, designated heme a, heme b and heme c. Heme b is the most 
prominent and acts as the prosthetic group for most hemoproteins and is thought to 
be the heme involved in regulating cellular processes (Figure 1.1.). Heme a and heme c 
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are found in the cytochrome a and cytochrome c proteins where they are covalently 











Figure 1.1 The structures of the most common hemes: heme b, heme a and heme c. 
 
The total heme content of the cell comprises the mostly inert heme that is tightly 
associated with hemoproteins such as cytochromes and the free heme pool which is 
available for regulatory protein binding and signalling. The protein-bound fraction is 
much larger than the free heme fraction, and represents the majority of cellular heme. 
As the free heme pool is smaller and much more difficult to investigate, it is much less 
understood. Questions remain over its concentration, cellular distribution, oxidation 
state and dynamics – how it is controlled and how it responds to different stimuli. In 
theory, the labile heme pool contains heme that is newly synthesised, as well as heme 







1.2 Toxicity of free heme 
 
A further consideration is that free heme is cytotoxic (Kumar and Bandyopadhyay 2005). 
Excess free heme catalyses the production of reactive oxygen species (ROS). It is an 
abundant source of redox-active iron that can participate in the Fenton reaction to 
produce toxic free hydroxyl radicals. These free radicals can damage lipids, proteins and 
DNA. The hydrophobicity of heme allows it to intercalate into lipid bilayers, promoting 
lipid peroxidation which enhances permeability and membrane disorder, this leads to 
cell lysis and cell death (Schmitt et al. 1993).  Hemin also catalyses the degradation of 
proteins into peptide fragments (Aft and Mueller 1984). Heme iron directly interacts 
with H2O2 to induce a lipid peroxidation of low-density lipoprotein (Klouche et al. 2004). 
Hemin treatment also leads to deletion of mitochondrial DNA, affecting expression of 
proteins such as cytochrome c oxidase and Bcl-xl thus leading to apoptosis (Suliman et 
al. 2002). 
 
As well as the direct oxidative damage that free heme can cause, it can also activate the 
endothelium, leading to vascular dysfunction and stimulation of the immune response, 
promoting acute inflammation and associated tissue damage (Dutra and Bozza 2014). 
Injection of heme into mice causes vascular permeability, leukocyte migration from the 
vasculature to surrounding tissues, and increase of acute-phase proteins (Wagener et al. 
2001). Excess heme in the blood activates endothelial cells by binding to toll-like 
receptor 4 (TLR4) which activates intracellular NF-κB signalling leading to the induction 
of the adhesion molecules: intercellular adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule 1 (VCAM-1), E-selectin, P- selectin, and von Willebrand factor (vWF) 
(Belcher et al. 2014). Heme also induces production of the cytokine interleukin-8 (IL-8) 
by endothelial cells (Natarajan et al. 2007) and by neutrophils (Graça-Souza et al. 2002). 
IL-8 is the major cytokine involved in neutrophil migration and adhesion to endothelial 
cells and therefore heme can also activate neutrophils for chemotaxis and infiltration. 
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Heme itself can also act as a chemoattractant to neutrophils (Porto et al. 2007). Once 
recruited, heme also stimulates production of ROS by neutrophils (Porto et al. 2007), 
further promoting oxidative damage of the vasculature and tissue injury (Mócsai 2013). 
Heme also activates macrophages through TLR4 binding, inducing production of the 
chemokines tumour necrosis factor α (TNFα), keratinocyte-derived chemokine (KC), 
CD14 (Figueiredo et al. 2007) and leukotriene B4 (LTB4) (Monteiro et al. 2011). These 
chemokines are also involved in neutrophil recruitment. Heme also triggers the oxidative 
burst of macrophages, increasing ROS production (Figueiredo et al. 2007). Co-
stimulation of several cell types with heme and TNFα have also been shown to activate 
the programed necrotic cell death pathway to a much higher extent than either alone 
(Gozzelino et al. 2010). Taken together, this activation of the immune response earns 
heme a categorisation as a damage associated molecular pattern (DAMP). DAMPs are 
molecules derived from damaged cells or extracellular matrix that signal to the innate 
immune system that damage has occurred and a response may be necessary. While 
inflammation is a vital immune process, inappropriate or excessive activation can cause 
local damage and the production of ROS by macrophages and neutrophils that can 
further exacerbate the oxidative damage caused by heme (Soares and Bozza 2016).  
 




Figure 1.2. Free heme toxicty. 1. Free heme can cause direct oxidative damage to membranes, 
DNA and proteins. 2. Oxidised heme can damage membranes of red blood cells, leading to 
hemolysis. 3. Heme can recruit neutrophils triggering inflammation. 4. Heme can activate 
endothelial cells leading to vascular dysfunction. From Chiabrando et al., 2014.  
 
1.3 Regulation of cellular heme levels 
 
Despite these negative effects, all heme dependent processes, such as the incorporation 
of heme into hemoproteins as well as signalling by the free heme pool requires the 
dynamic mobilisation of free heme. Therefore, the availability of free heme needs to be 
tightly controlled. Understanding the properties of the free heme pool is critically 
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important for understanding the role of heme in cellular processes. Organisms control 
their heme levels by a concerted action of several different systems: heme synthesis and 
degradation, import and export, and sequestration and scavenging by proteins (Figure 
1.3).  
Figure 1.3. Regulation of cellular heme levels. Heme is synthesised through 8 enzymatic steps in 
the mitochondria and cytosol. Extracellular heme can be exported through heme carrier protein 
1 (HCP1) and heme responsive gene-1 (HRG-1). Cytoplasmic heme can be scavenged by 
peroxiredoxin I (PRX1) or catabolised by heme oxygenase-1 (HO-1) or heme oxygenase 2 (HO-2). 
This liberates biliverdin (BV) that is converted to bilirubin (BR) by biliverdin reductase (BVR), CO 
and iron which is sequestered by ferritin (FtH). Cytoplasmic heme can also be exported by the 
Feline Leukemia Virus subgroup C receptor (FLVCR) and ATP-binding cassette, sub-family G, 






1.4 Regulation of heme synthesis 
 
Heme biosynthesis requires eight conserved enzymes and starts in the mitochondria 
(Wang and Pantopoulos, 2011). 5-Aminolevulinic acid (ALA) is synthesised by the enzyme 
ALA synthase (ALAS) from succinyl-CoA and glycine. ALA is exported to the cytosol where 
the next four enzymatic steps are carried out ending with the synthesis of 
protoporphyrinogen IX, which is transported back into the mitochondria where the last 
three conversions are carried out. In the mitochondria, it is oxidised to protoporphyrin 
IX and an Fe2+ iron is inserted by ferrochelatase in the last step of the pathway. Heme is 
then exported back to the cytosol for incorporation into apoproteins to form 
hemoproteins (Ajioka et al., 2006). The only mitochondrial heme exporter currently 
known is Feline Leukemia Virus subgroup C receptor 1 b (FLVCR1b). Overexpression of 
FLVCR1b promotes heme synthesis, whereas silencing it causes accumulation of heme 
in mitochondria (Chiabrando et al. 2012). 
 
There are two isoforms of ALAS in mammals – ALAS1 and ALAS2. ALAS1 is a 
housekeeping version of the enzyme, that is expressed in all tissue, whereas ALAS2 is 
specific to erythroid cells. In non-erythroid cells, it is ALAS that controls the rate of heme 
synthesis at the first step of the pathway. In erythroid cells that require large amounts 
of heme for synthesis of hemoglobin the rate limit is imposed by ALAS2. ALAS2 however, 
is not regulated by heme levels but by the supply of iron (Sassa, 1990; Ponka, 1997). 
 
In cells that express ALAS1, its expression is subject to negative feedback regulation by 
its product, heme (Marks et al., 1988). This was found to be due to inhibition by heme 
of translation of ALAS1 by destabilisation of mRNA, thereby decreasing its half-life (Drew 
and Ades, 1989; Hamilton et al., 1991).  Runoff transcription experiments showed that 
neither adding nor sequestering heme affected the rate of transcription in primary chick 
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hepatocytes, however sequestering heme did nearly triple the half-life of ALAS1 mRNA 
(Hamilton et al., 1991). ALAS also contains several 'heme regulatory motifs (HRM). 
Binding of heme to these Cys-Pro motifs inhibited the translocation of ALAS from its site 
of synthesis in the cytosol into the mitochondria where it acts (Lathrop and Timko, 1993; 
Munakata et al., 2004). Site directed mutagenesis that replaced the cysteine residues 
with serines reversed this inhibition and allowed ALAS1 to accumulate in mitochondria 
independent of hemin levels (Munakata et al., 2004). 
 
1.5 Regulation of heme degradation 
 
Although heme can regulate its own synthesis, an increase of free heme in the cytoplasm 
can also result from the turnover of hemoproteins, due to either natural catabolism of 
hemoglobin or oxidative stress-induced protein fragmentation. Heme oxygenase (HO) 
breaks down heme into ferrous iron (Fe2+), carbon monoxide and biliverdin. Carbon 
monoxide and biliverdin can act as antioxidants, protecting the cell from the pro-oxidant 
effects of heme. While, Fe2+ is also an oxidant that can act as a Fenton reactor to produce 
toxic free radicals (OH•), increased levels of Fe2+ promote synthesis of the protein ferritin 
that sequesters free iron, thereby protecting the cell from its oxidising effects (Gozzelino 
and Soares 2014). Therefore regulation of this system could determine whether the 
action of heme oxygenase acts a pro- or anti-oxidant and the enzyme can be thought of 
as a regulator of iron homeostasis (Ryter and Tyrrell 2000; Igarashi and Watanabe-
Matsui 2014). There are three isoforms of heme oxygenase: HO-1, HO-2 and HO-3. HO-
1 is an inducible form of the enzyme whereas HO-2 is constitutively expressed and 
participates in routine turnover of free heme (Maine et al. 1986). HO-1 and HO-2 are 
products of two different genes and share only 45% sequence homology, but their 
catalytic site regions do have 100% secondary structure homology (Kutty et al. 1994).  
The only response element in the promoter region of the HO-2 gene is the glucocorticoid 
response element (Raju et al. 1997). The HO-2 protein has two conserved Cys-Pro HRMs 
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(Mccoubrey et al. 1997) that form a reversible thiol/disulfide redox switch that indirectly 
regulates HO-2 activity by modulating substrate affinity (Yi et al. 2009). This allows HO-
2 to sense the redox state of the cell and link it to heme metabolism – under oxidative 
conditions heme catabolism increases, reducing the concentration of the pro-oxidant 
molecule and producing the anti-oxidants CO and biliverdin.  
The HO-3 gene was first identified in rat with the predicted protein sharing 90% 
sequence similarity with HO-2 and including two Cys-Pro motifs (McCoubrey et al. 1997). 
The protein was then expressed in E. coli but found to only have very low levels of 
catalytic activity and a regulatory role for HO-3 was suggested. However, since then, HO-
3 protein expression has not been detected in any tissue and remains an elusive and 
poorly investigated gene. More recently, efforts to isolate the previously reported gene 
failed but instead found two related psuedogenes HO-3a and HO-3b derived from HO-2 
transcripts but with no function (Hayashi et al. 2004).  
 
1.5.1 Regulation of HO-1 by heme 
 
To complement its inhibition of synthesis, heme can also promote its degradation to 
protect the cell from its oxidative effects. Heme acts through the transcription factor 
Bach1 (Figure 1.4.).  The hmox1 gene has several upstream enhancers that include the 
Maf recognition element (MARE) which can be bound by heterodimers of small Maf 
proteins (Kataoka et al., 2001). Bach1 is one such protein that can bind to MAREs with a 
small Maf protein to repress transcription of HO-1 (Sun et al. 2002). Evidence for this 
comes from co-transfection of a plasmid encoding Bach1, with a plasmid with both HO- 
1 and a luciferase reporter that showed that heme oxygenase expression was inhibited. 
Footprint analysis showed that Bach1 alone could not bind to DNA but when MafK was 
also added, the MARE sites were protected from DNA degradation. The presence of 
heme greatly inhibited the binding of Bach1-MafK to DNA  and in  bach1-/- knockout mice 
the level of HO-1 was much higher than in wild type (Sun et al., 2002).  Heme binds to 
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CP motifs in Bach1 and by a presumed conformational change inhibits DNA binding, 
displacing Bach1 from MAREs in favour of the transcription factor Nrf2 (Ogawa et al. 
2001; Sun et al. 2004). Chromatin immunoprecipitation analysis showed that heme 
displaced Bach1 from the hmox1 enhancer with the subsequent binding of Nrf2 (Sun et 
al., 2004). In addition to preventing Bach1-DNA binding, heme binding also triggers 
nuclear export of Bach1. Immunofluorescence microscopy showed that FLAG-tagged 
Bach1 localised to the nucleus but after stimulation with hemin it instead accumulated 
in the cytoplasm (Suzuki et al. 2004). Transcription of HO-1 is therefore regulated by 
balancing activation and repression. Heme increases expression by alleviating repression 
rather than activation of an activator.  
 
 
Figure 1.4. The regulation of heme oxygenase-1 (HO-1) by Bach1. The Bach1-MafK dimer binds 
to the Maf recognition element (MARE) and represses transcription of HO-1. If the free heme 
pool increases, heme binds to Bach1 and displaces it from the DNA, triggering its nuclear export. 






The full structure of Bach1 has not been solved, although the BTB domain in isolation 
has (Ito et al. 2009). The amino acid sequence does contain six CP motifs that are 
characteristic of heme regulatory motifs (Oyake et al. 1996) and when mutated abolish 
the ability of Bach1 to repress transcription of HO-1 (Ogawa et al. 2001). The protein 
binds at least 5 heme molecules, but a fragment containing only the first two CP motifs 
(those nearest the N-terminus and the BTB domain) did not show any heme binding (Hira 
et al. 2007). Mutation of CP3, CP4, CP5 and CP6 in turn reduced the heme binding 
potential of the protein by one equivalent indicating that each binds one molecule of 
heme, as well as the existence of a fifth heme binding site. A mutant with CP3 and CP4 
mutated to alanine lost its sensitivity to heme with respect to nuclear export, but 
mutating all CPs except CP3 and CP4 still caused Bach1 to be exported out of the nucleus 
in the presence of heme, indicating that heme binding to one or both of these sites is 
critical for the depletion of Bach1 in the nucleus (Suzuki et al. 2004). Although there is 
no evidence that certain CP sites are important for DNA binding, it has been suggested 
that CP5 and CP6 are implicated due to their positions flanking the bZip domain (Figure 
1.5). 
 





1.5.3 Regulation of HO-1 by other factors 
 
Although heme is the most potent inducer of HO-1, other stimuli that promote 
transcription are transition metals, H2O2, 𝛽-amyloid, dopamine, kainic acid, cytokines, 
prostaglandins, endotoxin, and vasoactive compounds, as well as other pro-oxidants and 
inflammatory stimuli. It is also induced by heat shock, radiation, hypoxia and hyperoxia, 
hyperthermia and ultraviolet irradiation. These can all be grouped under the title of 
oxidative stressors which activate signal transduction pathways and transcription factors 
- such as members of the NF-E2, HSF, AP-1, and NF-κB families - that regulate hmox1 
transcription (Alam and Cook 2007).  
 
It is unclear why cells respond to oxidative stress by increasing catabolism of free heme. 
One possibility is that oxidative stress is particularly dangerous for hemoproteins, which 
become denatured and release free heme. As heme is also an oxidant, without its 
degradation by HO-1, the cell could become quickly overwhelmed by the original oxidant 
as well as the heme released. Alternatively, the production of the anti-oxidant CO and 
biliverdin molecules are so beneficial to the cell that the sacrifice of heme is worthwhile. 
CO can bind to the heme of hemoproteins, inhibiting their oxidation, protecting the 
protein from heme-mediated oxidation and preventing further heme release (Epiphanio 
et al. 2007). 
 
1.6 Incorporation of heme into hemoproteins 
 
The rate of heme acquisition in the cell has to be proportional to demand and the biggest 
demand for heme comes from newly synthesised apo-hemoproteins. Synthesis of heme 
and synthesis of apo-hemoproteins is therefore quite integrated. Heme can induce the 
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expression of α- and β-globin genes through binding of Bach1 causing its removal from 
MARE sequences in their promoter (Tahara et al. 2004). 
 
Heme also regulates translation through the kinase heme regulated inhibitor (HRI). HRI 
is a serine/threonine kinase that can phosphorylate and thereby inhibit the transcription 
factor eIF2α. HRI autophosphorylates and dimerises to form a stable heme-sensing 
complex. Further heme binding through Cys-Pro HRMs prevents further 
autophosphorylation of Thr485 which keeps HRI inactive and unable to phosphorylate 
eIF2α (Chen 2007). 
 
1.7 Heme export and import 
 
There are two heme exporters at the cell surface – FLVCR1a and the ATP-binding 
cassette, sub-family G, member 2 (ABCG2). Overexpression of FLVCR1a leads to a 
decrease of cellular heme and silencing causes raised heme levels (Quigley et al. 2004). 
In mice without FLVCR1a, heme and iron accumulated in the liver and HO and ferritin 
were upregulated, indicating that the cell tries to overcome the lack of export by 
increasing degradation (Vinchi et al. 2014). Export of heme by FLVCR1a is dependent on 
the extracellular concentration of the heme-binding proteins hemopexin and albumin 
(Yang et al. 2010). Hemopexin can bind directly to FLVCR1a and may immediately bind 
the heme that is exported, allowing the channel to open for another molecule of heme. 
It is possible that albumin can also bind to the channel, although it has a much lower 
affinity for heme than hemopexin, and so export to albumin would be slower and 
therefore binding of different heme-binding proteins to FLVCR1a could regulate its heme 
export. 
ABCG2 is a member of the ABC transporter family that can transport a wide variety of 
substrates (Mao and Unadkat 2005). Expression of ABCG2 is induced in HeLa cells after 
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stimulation of heme synthesis, potentially as part of the response to deal with excess 
heme (Chiabrando et al. 2012). In human embryonic kidney cells, heme-induced cell 
death was reduced when ABCG2 was overexpressed (Wagener et al. 2013). However, 
Abcg2−/− mice accumulate PPIX rather than heme in erythroid progenitors so the exact 
physiological role of ABCG2 with respect to heme is still not completely understood 
(Zhou et al. 2005). 
There are certain heme importers that have been identified; heme responsive gene-1 
(HRG-1) is expressed in endosomes and lysosomes and transports heme from the inside 
of these vesicles into the cytoplasm for further intracellular processing (Rajagopal et al. 
2014). The cytoplasmic membrane transporter heme carrier protein 1 (HCP1) can also 
import heme into the cell (Shayeghi et al. 2005). Regulation of HCP1 expression is linked 
to the expression of HO-1, with induction of HO-1 leading to increased uptake of heme 
and overexpression of HCP1 leading to an induction of HO-1 (Latunde-Dada et al. 2006). 
These transporters presumably act to remove heme from the extracellular space for use 
or degradation in the cell, thereby protecting the extracellular space from the cytotoxic 
effects of heme. 
 
1.8 Heme scavenging 
 
As well as degradation by HO-1, another intracellular protection against free heme is the 
protein peroxiredoxin I (Prx1), which is also known as Heme-Binding Protein 23 (HBP23). 
Prx1 acts as a heme scavenger that neutralises the pro-oxidant activity of free heme in 
the cytoplasm, nuclear matrix, mitochondria, and peroxisomes (Immenschuh et al. 
2003). Its expression is also induced by hemin (Immenschuh et al. 1997), presumably to 




Extracellular heme has the same toxic effects as intracellular heme and can cause 
oxidative damage. Cells rely on the scavenging and sequestration of extracellular heme 
by extracellular proteins, and the main heme-neutralising proteins are haptoglobin and 
hemopexin. Lysis of red blood cells releases hemoglobin and free heme into the 
bloodstream; this constantly occurs at a low level as erythrocytes age, and controlled 
degradation of red blood cells that have reached an age of about 120 days takes place 
in the liver and spleen (Shibahara 2003). The free heme released from these processes 
needs to be quickly neutralised to prevent it damaging surrounding vasculature and 
tissue. Haptoglobin is a glycoprotein produced mainly in the liver and then circulates in 
the bloodstream. Binding of haptoglobin to hemoglobin protects the vasculature from 
hemoglobin-driven lipid peroxidation (Van Vlierberghe et al. 2004) with haptoglobin 
forming a stable complex with hemoglobin that is then internalised by the 
reticuloendothelial system. Binding to the CD163 receptor on the surface of macrophage 
cells triggers internalisation of the haptoglobin-hemoglobin complex and induction of 
HO-1 (Philippidis et al. 2004). After endocytosis, the complex is degraded in lysosomes 
and the heme can be catabolised in the cytosol by HO-1 (Moestrup and Møller 2004).  
 
Hemoglobin that does not become bound by haptoglobin is quickly oxidised, for example 
when the capacity of haptoglobin is exceeded. When confined inside red blood cells, 
hemoglobin exists as a tetramer with the iron of heme in a reduced state (Reiter et al. 
2002). However, after release hemoglobin dissociates into a dimer which reveals heme 
for oxidation to the ferric state, becoming methemoglobin. Methemoglobin then 
releases its free heme into the bloodstream (Ascenzi et al. 2005). Hemopexin is a 
glycoprotein that binds heme with very high affinity, to reduce its toxicity, thereby acting 
as an antioxidant. Hemopexin bound to heme is then internalised by CD91 (LDL receptor-
related protein 1), which is expressed mostly in the liver but also by macrophages 
(Hvidberg et al. 2005). As with the haptoglobin system, once endocytosed, the heme is 
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released from hemopexin which is degraded in the lysosome and the heme is released 
for further catabolism or recycling.  
 
Albumin can bind heme with an affinity 104 times lower than hemopexin, however, it is 
much more abundant than hemopexin which might compensate for its low affinity. 
Heme binding by albumin can also help protect against heme-mediated oxidative 
damage (Fasano et al. 2007). α1-Microglobulin is a plasma protein that is cleaved by free 
heme into an active form that can then catabolise free heme (Allhorn et al. 2002). α1-
Microglobulin expression is induced by heme and ROS and can protect skin cells from 
heme-mediated damage as well as protecting and repairing extracellular collagen fibrils 
(Olsson et al. 2011). High- and low-density lipoproteins (HDL and LDL, respectively) can 
also bind heme and then complex with hemopexin (Hvidberg et al. 2005) or be cleared 
via the CD36 and CD68 scavenger receptors expressed on macrophages (Camejo et al. 
1998). 
 
As outlined above, there are multiple levels of control for heme levels emphasising the 
importance for organisms of regulating the concentration of this potentially damaging 
molecule. As well as control of synthesis, cells have numerous responses to deal with 
excess free heme (Figure 1.6.). When these systems are overwhelmed or fail to act 





Figure 1.6. Mechanisms for control of free heme. Lysis of red blood cells (RBC) leads to release 
of hemoglobin (Hb) which is scavenged by haptoglobin (Hp) and can be internalised by the CD163 
receptor. Hemoglobin that is not scavenged by haptoglobin is oxidised and releases free heme 
which can be scavenged by hemopexin (Hx) and internalised by the CD91 receptor. Further 
buffering capacity is provided by albumin, HDL, LDL and α1-microglobulin. Once inside the cell, 
heme can be catabolised by heme oxygenases. From Larsen et al., 2012. 
 
1.9 Dysregulation of heme levels and heme in disease 
 
The cellular free heme pool can conceivably increase after extracellular heme overload, 
increased heme synthesis, accelerated hemoprotein breakdown, impaired incorporation 




1.9.1 Hemolytic diseases  
 
Hemolysis or rhabdomyolysis can release hemoglobin or myoglobin respectively into the 
extracellular space which can subsequently release free heme. If the buffering capacity 
of hemopexin is exceeded, then the free heme released can contribute to the 
pathogenesis of a range of disease. Hemolytic anemia, sickle-cell anemia, malaria, 
trauma and bleeding are typical causes of increased free plasma heme (Schaer et al. 
2013) that triggers vascular and organ dysfunction and leads to adverse clinical effects . 
Sickle cell disease is a genetic disorder caused by a mutation in hemoglobin, which leads 
to the production of abnormally shaped red blood cells that are prone to intravascular 
hemolysis. In sickle cell anemia, haptoglobin and hemopexin levels are both depleted 
(Muller-Eberhard et al. 1968).  
In sepsis, depleted hemopexin has been associated with more severe disease and fatal 
outcomes (Larsen et al. 2010). 
Polymorphisms in the hmox1 and hp2 (haptoglobin) genes as well as increased heme in 
the blood cause an increased susceptibility to malaria (Mendonça et al. 2012). Higher 
amounts of extracellular heme and lower amounts of hemopexin are associated with 
worse outcomes in malaria patients (Elphinstone et al. 2016). In mouse models of the 
disease, administration of free heme is sufficient to trigger the onset of cerebral malaria 
in mice infected with the Plasmodium strain that does not trigger cerebral malaria 
naturally (Ferreira et al. 2008), indicating that heme itself can exacerbate the disease. 
Destruction of red blood cells in malaria also hinders distribution of oxygen around the 
body, contributing to lactic acidosis, a principal pathophysiological feature of malaria 
(Miller et al. 2002).  
Oxidised heme is also a source of ROS and RNS that can damage the phospholipid 
membranes and proteins of red blood cells, contributing to aging and lysis of these cells 
(Rifkind and Nagababu 2013). Theoretically, in disease states where hemolysis is 
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triggered by other factors, the oxidation of heme could contribute to the continuation 
of the disease state by the further damage and lysis of red blood cells. After the release 
of free heme and the saturation of hemopexin, heme is distributed to cells in the 
vasculature, including endothelial cells and leukocytes where it can contribute to the 
inflammatory pathologies of disease.  
 
1.9.2 Neurodegenerative conditions 
 
Alzheimer’s disease (AD) is a neurodegenerative disease characterised by neuritic senile 
plaques (SP), which predominantly contain amyloid-β (Aβ) peptides, and tau-containing 
neurofibrillary tangles (NFT) mainly in the frontal cortex and hippocampus regions of the 
brain (Selkoe and Hardy 2016). Higher levels of free iron are observed in both the 
plaques and the tangles producing ROS and contributing to disease progression and 
cognitive impairment (Smith et al. 1997). This could be due to increased levels of HO-1 
found in plaques (Schipper 2000). Ferrochelatase is upregulated in the AD brain 
suggesting increased levels of heme synthesis (Atamna 2006). Hemoglobin is also found 
to aggregate with Aβ peptides in plaques (Wu et al. 2004). Free heme can also bind 
directly to Aβ through Arg5, Tyr10, and His13 residues, forming an active site with ROS 
generating and modest peroxidase activity (Ghosh et al. 2015). However, heme can also 
interact with hydrophobic residues of Aβ peptide secondary structure thereby blocking 
dimerization and higher order aggregation of the peptides (Zhao et al. 2013). In this role, 
heme would be protective against AD. Despite all these findings the pathogenic 
significance of heme in neurodegeneration in AD is not completely understood but it 
seems heme is significantly involved in AD. 
 
Parkinson’s disease (PD) is a movement disorder characterized by progressive 
degeneration of dopaminergic neurons, formation of α-synuclein-containing fibrillar 
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inclusions (Lewy bodies) in dopaminergic neurons and variable depletion of 
noradrenergic neurons and serotoninergic cells (Dauer and Przedborski 2003). HO-1 
expression is observed in the Lewy bodies and astroglia (Schipper et al. 1998). Whether 
free heme has a role in PD has yet to be investigated. 
 
HO-1 has been implicated in the pathobiology of numerous other degenerative and non- 
degenerative CNS condition. HO-1 localizes to diseased motor neurons in amyotrophic 
lateral sclerosis (Calingasan et al. 2005), Pick bodies in subjects with frontotemporal 
dementia, NFT in cases of progressive supranuclear palsy, and ballooned neurons in 
corticobasal degeneration (Castellani et al. 1995). It is conceivable that induction of HO-
1 may contribute to the pathological brain iron deposition and oxidative damage that 





Cancer cells are hyperproliferative, have a high oxygen requirement and therefore an 
increased demand for hemoproteins and therefore heme itself. 
A number of studies have demonstrated a positive association between high intake of 
red meat and colorectal cancer (Hooda et al. 2014). Red meat is high in heme and heme 
is readily absorbed in the gut. Mice fed with heme had gut epithelial hyperproliferation 
and decreased apoptosis (IJssennagger et al. 2012). Microarray analysis of their colon 
mucosa showed differential regulation of 3710 genes, with a downregulation of the 
inhibitors of proliferation, Wnt inhibitory factor 1, Indian Hedgehog, bone 
morphogenetic protein 2 and Interleukin-15 and upregulation of the growth factors 
amphiregulin and epiregulin. The oxidative properties of heme can increase the 
production of N-nitroso compounds in the human intestine which could oxidise DNA and 
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lipoprotein and perhaps increase the rate of mutation of DNA (Lunn et al. 2007).  
Although less epidemiological data is available for other cancers, there is also evidence 
for increased dietary heme increasing the risk of oesophageal and stomach cancer and 
pancreatic cancer (Hooda et al. 2014). 
 
Heme can also regulate the phosphorylation activity of various proteins of the MAPK 
pathway (Ye and Zhang 2004) which has a central role in cell growth and transformation 
(Seger and Krebs 1995). In HeLa cells, heme can activate the kinase Raf, which was 
originally identified as an oncogene, leading to activation of the downstream targets 
ERK1/2 and MEK1/2  (Ye and Zhang 2004). Heme deficiency lead to increased levels of 
the p53 protein which is a tumour suppressor and the negative cell cycle regulator p21 
leading to decreased proliferation. 
 
HO-1 levels are also elevated in the majority of cancers; however, the activity of HO-1 
varies, and, therefore, heme metabolism can be dramatically altered in tumours (Wegiel 
et al. 2014). 
 
1.9.4 Cardiac Diseases 
 
Atherosclerosis is the thickening of the arterial wall as a result of invasion and 
proliferation of macrophages and foam cells and proliferation of smooth muscle, 
forming an atherosclerotic plaque. Free heme in the bloodstream can initiate the 
inflammatory response and recruit macrophages to the endothelium. Inside the cell, 
stimulation of NADPH oxidase by heme and subsequent production of cytosolic ROS has 
been shown to induce smooth muscle proliferation and formation of atherosclerotic 
plaques (Moraes et al. 2012). This effect is attenuated by the inhibition of heme 
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oxygenase-1. Double knockout mice – ApoE-/- and Bach1-/- - developed less 
atherosclerotic plaques than ApoE-/- mice (Watari et al. 2008). Free heme can also oxidise 
lipids and lyse red blood cells, debris of which can contribute to plaque formation 
(Viktoria et al. 2014).  
 
In mice subjected to coronary ligation induced ischemia, higher heme levels were found 
in hearts leading to worse cardiac function (Sawicki et al. 2015). Mice who overexpressed 
ALAS2 had hearts that displayed increased heme content, higher oxidative stress, 
exacerbated cell death, and worsened cardiac function due to the presence of excess 
heme. In failing hearts removed from transplant patients, an excess of heme was also 
observed (Khechaduri et al. 2013). ALAS2 was also significantly upregulated but HO-1 
was not.  
 
Heme can bind to myosin light chain-1 protein, alter human ventricular cardiomyocyte 
morphology and hinder their ability to contract (Alvarado et al. 2015). This may in part 




Type 2 diabetes mellitus is characterized by hyperglycaemia, insulin resistance, and a 
relative impairment in insulin secretion. Patients with diabetes also display endothelial 
dysfunction that is likely due to high ROS mediated by hyperglycaemia (Abraham et al. 
2003). Diabetics are also more susceptible to atherosclerosis (DeFronzo 2010).  In muscle 




Induction of HO-1 by cobalt protoporhyrin improved insulin sensitivity in the diabetic 
obese rat model (Nicolai et al. 2009). Further, induction of HO-1 selectively enhanced 
polarization toward an anti-inflammatory M2 macrophage phenotype and reduced 
pericardial adiposity and cardiac injury in diabetic cardiomyopathy in obese rats (Jadhav 
et al. 2013). Improved anti-oxidative potential was reported in spontaneously 
hypertensive rats after treatment with hemin (Umekawa et al. 1990). Hemin therapy 
lowered blood pressure, decreased glycemia, reduced insulin resistance as well as 
proteinuria/albuminuria, and enhanced glucose transport.  
 
1.9.6 UVA irradiation 
 
UVA irradiation of skin fibroblasts induces HO-1 through the generation of reactive 
oxygen species (Basu-Modak S 1993) which is dependent on cyclooxygenase (Basu-
Modak et al. 1996). After UVA irradiation, or treatment with H2O2, heme is released from 
microsomal hemoproteins in a manner that is also dependent on cyclooxygenase and 
precedes induction of HO-1 (Kvam et al. 1999). UVA irradiation is a carcinogen and 
causes local inflammation and it is possible that the involvement of heme and HO-1 
contributes to these pathologies (Tyrrell 2004). 
 
1.10 Structure of hemoproteins 
 
Protein chains can bind heme b through both coordination of the available axial positions 
of the iron by amino acid side chains as well as by hydrophobic interactions with the 
porphyrin ring and hydrophilic interactions with the propionic acid units. The presence 
and position of amino acids not only define heme binding sites in proteins but are critical 
for controlling the protein’s heme chemistry. Heme proteins are especially prominent in 
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dioxygen chemistry, transporting O2, effecting redox chemistry or acting as a sensor for 
O2 or CO.  
Analysis of the heme-containing proteins deposited in the PDB revealed that in 77% of 
heme-binding proteins, the heme scaffold was α-helical, while 13% were mostly β-sheets 
and the remaining 10% were a mix (Reedy and Gibney 2004). The overall fold of the 
protein determines the orientation of the individual heme-interacting amino acids. The 
most commonly found coordination ligand is the imidazole group of histidine. 
Pentacoordinate binding involving one histidine is typical of oxygen carrier proteins such 
as hemoglobin and myoglobin. A hexacoordinate heme is typical of electron transfer 
proteins with two histidine ligands often being involved (bis-histidine coordination), and 
is the second most common binding pattern as illustrated by cytochrome b.  Histidine 
may also be found in combination with other axial ligands such as methionine in 
cytochrome c. While heme is covalently bound to all but one cytochrome protein during 
bis-histidine coordination, in hemopexin, where heme is also coordinated to two 
histidines, binding is very strong but reversible. Cys is another coordinating heme ligand, 
such as in cytochrome P450s, while in heme catalase, the hydroxyl group of Tyr acts as 
the axial ligand (Rydberg et al. 2004). However, especially in proteins where heme is not 
a permanently bound prosthetic group, the heme binding site is not necessarily static 
and ligands can change during heme binding. As well as the axial ligands, heme binding 
sites are characterised by aliphatic and aromatic amino acids that interact with and 
stabilise the heme macrocycle. Polar amino acids can also contribute to heme protein 
binding site specificity and modulation of chemical properties by providing various 
hydrogen bond donors and acceptors.     
One of the unique features of the heme molecule is that there is significant electron and 
spin delocalisation around the ring, the iron and the axial ligands (Rovira et al. 1997). 
Significant charge transfer can occur between the iron and covalent ligands resulting in 
changes in the formal charge on the iron and the distribution of net charge and unpaired 
spin density through the macrocyle. This allows the formation of various different 
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species and changes in the oxidation state of the iron leading to different heme protein 
functions. In enzymatic hemoproteins such as peroxidases and cytochrome P450s, the 
iron reaches the Fe(V) oxidation state which is too unstable to occur in any other iron 
system, but delocalisation greatly reduces the net charge on the formal Fe(V) iron (Loew 
and Harris 2000). Another property of a protein-bound heme is the presence of multiple 
spin states, and these changes in spin state can also be integral to hemoprotein function. 
In hemoglobin and myoglobin the binding of O2 to the iron transforms the five-
coordinated, high spin quintet species to a six-coordinated, singlet species (Baldwin and 




Hemoglobin is a heme containing, oxygen transport protein present in all vertebrates. 
It has a globular structure and is composed of 2 α-chain subunits and 2 β-chain 
subunits, each forming a globin fold with a heme prosthetic group. Each ferrous heme 
iron is linked to the Nε of a His, denoted the proximal histidine (Figure 1.7). O2 can 
reversibly bind in a bent geometry to the Fe atom on the other side of the heme plane 
and is stabilised by hydrogen bonding to the distal histidine (Perutz 1979). The heme 
binding pocket is overwhelmingly hydrophobic and there are over 60 interactions of 4 
Å of less between the heme and the binding pocket (Perutz et al. 1968). Examples of 
particularly important interactions include van der Waals interactions with Val67, 
Leu88 and Val98, and π- π stacking with Phe42 (Park et al. 2006). 
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Figure 1.7. Human oxyhemoglobin (PDB 2DN1) showing the proximal and distal histidines in blue 
and other residues involved in heme binding in green. Heme is orange and O2 is red. The figure 
was created using The PyMOL Molecular Graphics System, Schrödinger, LLC. 
 
1.10.2 Cytochrome b5 
 
Cytochromes b5 are a ubiquitous family of hemoproteins involved in electron transport 
reactions. There are two isoforms of cytochrome b5 in vertebrates, Cyb5A and Cyb5B, as 
well as a number of other protein domains with the same fold covalently associated with 
other redox domains in proteins such as flavocytochrome cytochrome b2,and sulphite 
oxidase (Lederer 1994). The cytochrome b5 fold comprises two hydrophobic cores 
flanking a 5-stranded β-sheet. The N-terminal core contains the heme binding site 
between two α-helices, α2 and α5. The heme iron is bis-coordinated by two His residues 
with the propionate side chains facing out of the binding pocket. In human CYB5B, the 
heme iron is coordinated by His39 and His63 (Figure 1.8.) and the rest of the binding 
pocket is highly hydrophobic with Leu23, Ile25, Val32 and Leu71 side chains forming 
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hydrophobic packing interactions with the porphyrin core as well as edge-to-face 









1.10.3 Cytochrome P450s 
 
Cytochrome P450s (CYP450s) are one of the largest families of enzymes, with over 
18,000 identified and 57 in humans. CYP450s are monoxygenases, and transfer a single 
oxygen from their heme iron to a variety of non-polar substrates. They are heavily 
involved in the detoxification of xenobiotic molecules by hydroxylation, epoxidation and 
heteroatom oxidation. Many of them have unique structures but all have a conserved 
proximal Cys that provides a sulfur atom ligand to a heme iron. Their heme atoms 
undergo complex transitions during their enzymatic cycle, changing oxidation state, 
distal ligands and spin states (Loew and Harris 2000). The local structure around the Cys 
ligand is highly conserved; the Cys is located at the C-terminal end of the L helix where 
the Cys sulfur accepts an H-bond from a peptide NH group, which helps the heme reach 
Figure 1.8. Human CYB5B (PDB 3NER) showing the heme-binding pocket with the coordinating 
His residues in blue and contributing hydrophobic residues in green. Heme is in orange. The 




the required redox potential. There is more variation in the positioning of the I helix 
which lies over the surface of the heme and contributes groups that interact with the 
substrate and O2 (Poulos 2014).  
CYP3A4 is one of the most important, and also promiscuous CYP450 enzymes and 
metabolises half of all currently marketed drugs. This means that it is also responsible 
for a host of drug contraindications. It has a large cavity about the heme molecule which 
lies on a bed of mostly polar amino acids. In human CYP3A4, the heme is ligated by 
Cys442 (Figure 1.9.) and the propionates of the heme interact with the side chains of 
Arg105, Trp126, Arg130, Arg375 and Arg440. The side chains of Ile443 and Phe435 also 
lie under the heme macrocycle, providing hydrophobic contacts (Williams et al. 2004). 
The residues above the substrate cavity, help orientate the substrate in the correct 
position above the heme so that it can interact with the iron during the catalytic cycle.   
 
Figure 1.9. Human CYP3A4 (PDB 1W0F) showing the heme binding pocket and substrate cavity. 
Heme is in orange with the axial Cys in blue and other stabilising residues in green. The figure 






Catalases are a family of enzymes that catalyse the degradation of two molecules of H2O2 
to oxygen and two molecules of water. The largest class of catalase is the 
monofunctional heme-containing catalases that all have a common mechanism 
(Chelikani et al. 2004). In the first step, one molecule of hydrogen peroxide is reduced 
by the Fe(III) heme iron to produce water and a covalent Fe(IV)=O species with a 
porphyrin cation radical. This species then oxidises a second H2O2 and releases the ferryl 
oxygen species as water, regenerating the heme Fe(III) iron species. By catalysing the 
degradation of the pro-oxidant H2O2, catalase is an important enzyme in protecting the 
cell from oxidative damage. Human catalase forms a tetramer with a heme molecule at 
the interface between two domains (Putnam et al. 2000). The heme is pentacordinate 
with Tyr358 providing an axial ligand (Figure 1.10.), the strong electron-donating 
character of which may help prioritise binding of H2O2 over water. The tyrosinate ligand 
is also hydrogen-bonded to Arg354 which is in turn hydrogen-bonded to His218, which 
is then followed by Asp348, and this charge relay likely tunes the reactivity of the heme 
iron and stabilises its different oxidation states. The heme propionates interact with 
Arg72, Arg112 and Arg365, while Phe153 and Phe161 contribute to aromatic stacking 


















1.11 Heme measurement and heme sensors 
 
Although there have long been ways of studying heme structure and synthesis in vitro, 
as well as methods to study the total heme content in populations of cells, there are very 
few tools available that permit the study of the dynamics of free heme in live cells. 
Traditionally, cellular heme has been measured by indirect spectroscopic methods. This 
would typically involve either homogenising cell or tissue samples and treatment of the 
resultant lysates with pyridine in alkali so that the nitrogen ligands from protein-bound 
heme are replaced by pyridine, forming the pyridine hemochromogen which can be 
detected by absorbance spectroscopy (Paul et al. 1953). Alternatively, homogenised cell 
or tissue samples could be heated and the resultant lysate acidified to release heme from 
hemoproteins and remove the iron to convert the heme into PPIX. The fluorescence of 
PPIX would then be measured and assumed to equal the concentration of heme 
(Morrison 1965). A further method involves extracting heme from cells or tissues with 
Figure 1.10. Human catalase (PDB 1DGF) showing the heme-binding pocket with the heme in 
orange. The coordinating Tyr residue is shown in blue and the hydrogen-bonded charge relay 
residues in red. Other contributing hydrophobic residues are in green. The figure was created 




acetone and HCl and then analysing the material obtained by HPLC (Sinclair et al. 2001). 
More recently a new spectrophotometric method has been developed, wherein heme 
was extracted from cell free supernatants of Trypanosoma cruzi cultures with acidified 
chloroform (Lombardo et al. 2005). Then the relationship between the absorbance at 
388 nm, 450 nm and 330 nm was found to correlate to the concentration of hemin. After 
six days of parasite growth, with 0, 5, 15, and 30 µg hemin/ml of medium, the content 
of hemin in a cell-free supernatant was found to be 0.35 ± 0.22, 4.79 ± 1.38, 45.84 ± 4.50, 
and 72.34 ± 6.87 nmol/mL of supernatant, respectively. This assay is reportedly 15-30 
fold more sensitive and can detect hemin concentrations 4 fold lower than the pyridine 
hemochromogen method.  
Several molecular systems have been designed to provide direct spectroscopic readouts 
that may be correlated with heme binding. These so-called heme sensors are intended 
to address the challenge of measuring heme levels in live cells. For example, a heme 
sensor that utilised a fusion protein of enhanced green fluorescent protein (EGFP) and 
the heme binding protein apocytochrome b562 was used to monitor the fluorescence 
quenching of EGFP when heme binds to apocytochrome b562 (Takeda et al. 2003). No Kd 
was reported for heme binding, and the sensor was not used with any biological samples, 
although the potential for cell expression using a transfected plasmid was noted. 
The activity of horse radish peroxidase (HRP) on addition of hemin has also been used as 
the basis for a heme sensor (Masuda and Takahashi 2006). The apo-HRP could detect 
hemin, which could bind and activate the enzyme which then oxidises luminol in the 
presence of H2O2, producing chemiluminescence representing the amount of hemin 
present. The detection limit of this assay was estimated at 20 pM.  
A similar sensor based on the binding of heme to a heme-binding protein was also 
developed in 2013 by Koga et al. Three small molecule fluorophores - Alexa Fluor 350 
C5-maleimide (AF350), Alexa Fluor 555 C2-maleimide (AF555), and 2-(40- 
maleimidylanilino)naphthalene-6-sulfonic acid sodium salt (MIANS) were conjugated 
near the heme-binding site of HO-1 to an engineered Cys residue. Titration of hemin to 
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these sensors lead to quenching of the fluorophores’ fluorescence, with the HO-1-AF350 
construct having the lowest Kd of 1.44 ± 0.36 nM. The sensor was then used to detect 
heme released from different amounts of denatured hemoglobin. This sensor could 
reportedly detect heme at a concentration 10 fold lower than the cytb562–EGFP sensor 
of Takeda et al. It also improved over the HRP based sensor in that theoretically heme 
did not need to be extracted from samples before detection. The HO-1 sensor was 
further improved by mutation of Asp140 in the active site to a His residue, thereby 
removing the catalytic activity of the HO-1 enzyme (Taira et al. 2015). The mutated 
protein with the fluorophore AF555 had a Kd of 0.13 ± 0.02 nM, determined by a 
fluorescence titration with hemin. The improved sensor was then used to determine 
concentrations of 0.019 ± 0.003 and 1.757 ± 0.163 nmol heme/mg protein for non-
denatured and acidic acetone-treated samples of rat hepatic-microsomal fractions. 
 
Song et al. created a protein-based ratiometric heme sensor that relied on the binding 
of heme between two heme binding domains (IsdX1 and IsdC) that were each attached 
to a fluorescent protein (enhanced cyan fluorescent protein (ECFP) and enhanced yellow 
fluorescent protein (EYFP)). Heme binding brought the domains together causing energy 
transfer between the fluorescent domains (Song et al. 2015).  Titration of hemin into this 
system using the FRET ratio as the readout determined a Kd of 63.5 ± 14.3 nM. This 
construct was encoded into plasmids which were transfected into HeLa cells and used 
to monitor the increase in cellular heme after treatment of cells with 5 µM exogenous 
hemin. 20 min after the addition there was a clear increase in FRET ratio (IEYFP/IECFP) 
that reached a maximum after 100 min and had returned to baseline after 4 h. The 
concentration of free heme in the cytosol was estimated to be 25.6 ± 5.5 nM and the 
labile heme concentrations for mitochondria, endoplasmic reticulum, and nucleus were 




Hanna et al. recently developed a genetically-encoded heme sensor that is again based 
on the quenching of the fluorescent protein EGFP by heme binding to cytochrome b562, 
but also has another fluorescent protein Katushka 2 (mKATE2) that exhibits heme-
insensitive fluorescence (Hanna et al. 2016). The red fluorescence of mKATE2 is not 
affected by heme binding and therefore can be used to normalise the altered 
fluorescence of EGFP upon heme binding. A Kd of 10 nM was determined by titration of 
hemin and measurement of the ratio of fluorescence. Plasmids encoding the sensor 
were transfected into Saccharomyces cerevisiae and the cytosol was found to have more 
free heme (∼20–40 nM) than the nucleus or mitochondria (<2.5 nM).  
 
1.12 Important factors to consider for designing a heme sensor 
 
The first important consideration when designing a strategy for heme sensor 
construction is the ability to differentiate between protein-bound and free heme. This 
means that the sensor should to be able to reach the free heme pool without the need 
to treat the cells with any reagent that would release bound heme. This also gives rise 
to the second consideration - the affinity of the probe for heme. As the pool of free heme 
in the cell needs to be tightly regulated to minimise its toxicity, it has previously been 
found to be at nM concentrations. Therefore, the affinity of a sensor for heme should be 
around this level in order to effectively detect such low concentrations. It is also 
necessary for such sensors to detect small changes in analyte (i.e. heme) concentration 
in cells. To gain this sensitivity and accurately quantify the concentration and dynamics 
of an analyte, a sensor should be partially saturated with the analyte in the organelle of 
interest when the cell is at rest. In this context using whole sensor proteins could help 
achieve this high affinity. Any sensor also needs to be specific for heme and not detect 
its precursor PPIX or free iron. Another problem with heme sensing is that heme iron can 
exist in two principal oxidation states – ferrous and ferric. As heme is readily oxidised in 
vitro, nearly all experiments with exogenous heme use ferric heme (hemin). While most 
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heme sensors probably bind both forms, albeit with different affinities, the ability to 
distinguish the redox state of the free heme in cells more precisely would be a useful 
feature for future iterations in the design of these sensors, as currently very little is 
known about the oxidation state of the iron in the free heme pool. 
Although it has long been possible to measure cellular heme by lysing cells, being able 
to measure heme intracellularly is more accurate as there will be no loss or degradation 
of cell components during collection and lysis. Intracellular detection is also much more 
attractive for assessing heme levels in some sub-cellular compartments, as although it is 
possible to separate some organelles from a total cell lysate, this is not always the case, 
especially for organelles of the secretory pathway. Being able to direct sensors into the 
cell and even into specific organelles would give a more complete picture of the 
management and distribution of the free heme pool. Any sensor that is applied 
intracellularly should also be as non-invasive as possible and not disrupt the heme level 
of the cell or indeed, the overall metabolic state of the cell. This is a drawback for 
genetically encoded sensors as it is never really truly known what effect the genetic 
manipulation has on the cell, especially if stable integration into nuclear DNA is desired 
rather than use of a plasmid.  Further, triggering the cell to overexpress the heme sensor 
could put an unnatural energy demand on the cell.  
For the readout of a heme sensor, consideration should be given to the type of signal 
that is to be measured. Light-based measurements, e.g. fluorescence provide a high 
degree of sensitivity and are quick and easy to measure. A ‘turn-on’ sensor with an 
increasing signal upon heme-binding would provide easier detection and will give a more 
accurate representation of when the probe is fully saturated by heme. Also, in order to 
determine the amount of heme sensor in the cell, a fluorophore that is independent of 
heme concentration, but proportional to the sensor concentration is necessary. 
Alternatively, two fluorophores that are ratiometric – that is the ratio between their two 
fluorescence intensities changes on heme binding – is another solution as long as the 
ratio can be determined in the absence of heme and when completely saturated.  
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Further desirable features would be the ease of use and inexpensiveness of the sensor 
for its use in large scale applications. 
 
1.13 Aims and objectives 
 
The role of heme in physiological processes and disease is currently poorly understood. 
Indirect measurements have implicated heme in a number of diseases states (as 
discussed above). However, there is currently no way to directly assess heme levels in 
cells. Being able to measure and track heme in cells would greatly aid future efforts to 
understand the functions of heme and could help understand, diagnose and treat 
disease. Of particular interest is the effect of UVA irradiation on free heme levels and 
the effect this will have on the cell. Bach1 is the transcription factor that monitors and 
reacts to the heme level of the cell and it is expected that if heme levels of the cell rise 









The overall objective of this thesis is to develop a probe that can detect heme levels in 
cells which can be used to investigate the Bach1/HO-1 system and the effect of UVA 
irradiation on this system and the heme levels of the cell. 
1. Develop a sensor capable of measuring heme levels (Figure 1.11) 
a. Design a probe able to bind heme 







2. Use the probe to investigate the effects of UVA irradiation on cultured skin cells 
a. Test the suitability of the probe for use in cells for example, toxicity and 
uptake 
b. Treat cells with hemin and UVA irradiation and use the peptide to 
investigate heme levels 
 
3. Develop a probe to compete with Bach1 for heme, thereby modulating its DNA 
binding activity 
a. Express recombinant human Bach1 


















2 Materials and Methods  
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2.1 Solid Phase Peptide synthesis 
 
General: Peptides were prepared by Fmoc solid phase peptide synthesis (SPPS) (Palomo 
2014). Fmoc-protected amino acids were all obtained from NovaBiochem, with the 
exception of 7-azatryptophan (SigmaAldrich). Peptide grade DMF was purchased from 
Rathburn Chemicals. All other solvents were purchased from Fisher Scientific. 
The completeness of solid phase acylations or deprotection reactions was confirmed by 
the Kaiser test (Kaiser et al. 1970). A few beads of the resin were placed in an Eppendorf 
tube and 2-3 drops of the following solutions were added: 100 mM ninhydrin in EtOH, 
2.1 M phenol in EtOH and 0.02 mM KCN in pyridine.  The tube was heated and the 
presence of free/unacylated amino functions was indicated by a dark blue colouration 
of the beads. To estimate the loading of resins after derivatisation with the first amino 
acid, an Fmoc loading test was performed (Gude et al. 2002). Fmoc-protected-resin (10 
mg) in a graduated flask (10 mL) was treated with 2% DBU (1,8-diazabicycloundec-7-ene) 
in DMF (2 mL) and agitated gently for 30 min. The solution was then diluted to 10 mL 
with MeCN and 2 mL of this solution was further diluted to 25 mL with MeCN (test 
sample). A similar treatment was performed for the reference sample, but without the 
resin. Measurement of the test sample against the reference sample was performed 
using a Unicam Helios UV-Vis spectrophotometer, and the absorbance was recorded at 
304 nm. An estimate of the loading of the resin was then calculated using the equation:  
Fmoc (mmol/g) = (Asample –Aref) × 16.4/ mg of resin 
 
Peptide amides: Rink Amide MBHA (Merck Millipore) resin (0.25 g, 0.78 mmol/g) was 
pre-swollen in DCM (5 mL) in an SPPS cartridge (Activotec) for 1 h. The resin was treated 
with 20% piperidine in DMF (5 mL) and was agitated for 2 min, then the resin was drained 
under suction, and the process was repeated for 15 min.  The solvent was drained and 
the resin was washed with DMF (4 × 5 mL). A positive Kaiser test showed the successful 
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removal of the resin amino group protection. The first amino acid was then coupled 
using Fmoc-X(PG)-OH (4 eq) with PyBOP (4 eq), DIEA (6 eq) and HOBt (4 eq) in DMF (5 
mL) for 1 h with agitation. The solvent was drained and the resin was washed with DMF 
(4 × 5 mL). A negative Kaiser test confirmed the reaction of the resin amino groups with 
the first amino acid. Any remaining free amino groups were acylated by treatment with 
acetic anhydride (20 eq) and DIEA (6 eq) in DMF (5 mL) for 20 min. 
 
The remaining amino acids were coupled using an Activotec P11 automated peptide 
synthesiser using PyBOP as the coupling agent (3 eq), DIEA as the base (6 eq) and DMF 
as the solvent. Coupling reactions were at 60 °C for 35 min. Fmoc deprotection was with 
25% piperidine in DMF for 2 min followed by washing with DMF followed by 25% 
piperidine for 5 min at room temperature. Removal of the Fmoc group of the final amino 
acid was carried out on the automated peptide synthesiser. 
Cleavage from the resin and side chain deprotection was completed by treatment of a 
sample of the resin (125 mg) with TFA/H2O/TIS/EDT (4 mL, 92.5/2.5/2.5/2.5, v/v/v/v) for 
Cys-containing peptides, or TFA/H2O/TIS (4 mL, 95/2.5/2.5, v/v/v) for peptides without 
a Cys residue. The deprotections were carried out for 3 h at room temperature. The resin 
was removed by filtration and the filtrate was added to diethyl ether which resulted in 
precipitation of the peptide. The peptide was collected by centrifugation after washing 
with Et2O (3 times).  
Peptide acids: Wang resin (100-200 mesh, 0.25 g, 0.9 mmol/g) was pre-swollen in DCM 
(5 mL) in an SPPS cartridge for 1 h. The first amino acid was coupled using Fmoc-X(PG)-
OH (4 eq) with MSNT (4 eq), 1-Methylimidazole (2 eq) in DCM (5 mL), overnight with 
agitation. The solvent was drained and the resin was washed with DMF (4 × 5 mL). The 
synthesis was then continued as for the peptide amides. 
Analysis and Purification: Crude peptides were purified by semi-preparative RP-HPLC 
using a Dionex HPLC system equipped with a Phenomenex Gemini 5 µm C-18 (250 × 10 
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mm) column with a flow rate of 2.5 mL/min. The gradient elution system was 0.1% TFA 
in water (mobile phase A) and 0.1% TFA in acetonitrile (mobile phase B). The peaks were 
detected at 214 nm, 220 nm, 254 nm and 280 nm. The gradient was T=0 min B=5%, T=30 
min B=95%, T=45 min B=95%, T=45.1 min B=5%, T=52 B=5%. Purified peptides were 
lyophilised and stored at -20 °C. 
Purity was confirmed with analytical RP-HPLC which was performed using a Dionex 
UltiMate 3000 HPLC system equipped with a Phenomenex Gemini 5 µm C-18 (150 × 4.6 
mm) column with a flow rate of 1 mL/min. The gradient elution system was 0.1% TFA in 
water (mobile phase A) and 0.1% TFA in acetonitrile (mobile phase B). The peaks were 
detected at 214 nm, 220 nm, 254 nm and 280 nm. The gradient was T=0 min B=5%, T=10 
min B= 95%, T=15 min B=95%, T=15.1 min B=5%, T=18 min B=5%. 
Mass spectrometry: All peptides were characterised by electrospray mass spectrometry 
on either a Bruker microTOF LCS spectrometer with time of flight quantitation, or a 
Bruker MaXis HD ESI-QTOF coupled to a Thermo Scientific Dionex Ultra High 
Performance Liquid Chromatography (UHPLC) unit. Samples were prepared in 
acetonitrile or methanol. 
LC-MS/MS: The Chip-based analysis was conducted using an HPLC-Chip Cube system 
coupled to a 6520 quadrupole time-of-flight (QTOF) mass spectrometer (Agilent 
Technologies, Santa Clara, CA) operated in ESI positive-ion mode. Liquid 
chromatography was performed using a Large-Capacity Chip (II) with a 160 nL 
enrichment column and analytical column of 150 mm × 75 µM with Zorbax 300SB-C18 
packing material at 5 µm (G4240-62010, Agilent, Santa Clara, CA, USA). The ChipCube 
source was operated at 300°C with 5 L/min N2 drying gas, the capillary voltage set to 
1900V and fragmentor at 170V. The TOF MS scan range was from 300 – 1700 mass-to-
charge ratio (m/z) at an acquisition rate of 4 spectra per second. For MS/MS, 5 multiply 
charged precursor ions per spectra, having between 2 – 5 charges, were selected for 
MS/MS and thereafter excluded after collecting 2 spectra, then released after 0.1 min. 
The MS/MS mode mass range was from 50 – 1700 m/z at 3 spectra per second with the 
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collision energy set relative to the ion mass with the formula 3.6m/z / 100 - 4.8. The 
source was interfaced with an Agilent 1260/1200 series HPLC system consisting of a 1260 
Cap pump, 1200 Nano pump, 1200 Micro WPS and 1290 Infinity Thermostat (Agilent, 
Santa Clara, CA, USA). Between 0.2 and 1 µL sample was loaded on the enrichment 
column using the capillary pump flow with H2O + 0.1 % formic acid (FA) at a flow rate of 
4 µL/min. The sample was eluted onto the analytical column using the nano pump at a 
flow rate of 0.3 µL/min. Solvent A and B consisted of H2O + 0.1 % formic acid (FA) and 
ACN:H2O 90:10 with 0.1% FA. Gradient steps were as follows: 0-28 min from 3% B to 
50%B, 28-30 min to from 50% B to 100% B, 30-31 min 100%B, 31-32 min from 100% to 
3% B. Internal lock mass calibration was active during the run using one calibrant 
reference mass at 1221.9906 m/z. Data processing and file exporting was performed 
using the Masshunter Workstation software version B.50.00 (Agilent, Santa Clara, CA, 
USA). Automated MS/MS database searching was performed using Mascot v2.4.1 
(Matrix Science, MA, USA). 
 
2.2 Characterisation of heme-binding peptides 
 
CP3 KRSECPWLG Obtained: 60.2 mg, 28%. HPLC: Rt- 5.37 min. [Found (ESI+) 1074.5593 
[M+H]+, C47H75N15O12S requires 1074.5513]. 
CP4 SSVNCPFIS Obtained: 46.2 mg, 35%. HPLC: Rt- 5.82 min. [Found (ESI+) 952.4618 
[M+H]+, C41H65N11O13S requires 952.4557]. 
CP5 QQEPCPYAC Obtained: 32.5 mg, 67%. HPLC Rt- 5.24 min. [Found (ESI+) 1038.4072 
[M+H]+, C43H63N11O15S requires 1038.4019]. 
CP6 SAADCPLSF Obtained: 53.6 mg, 36%. HPLC: Rt- 5.78 min. [Found (ESI+) 909.4306 
[M+H]+, C39H59N9O14S requires 909.4135]. 
CP-IRP2 TPILCPFHL Obtained: 61.5 mg, 43%. HPLC: Rt- 6.61 min. [Found (ESI+) 1040.5574 
[M+H]+, C50H77N11O11S requires 1040.5597]. 
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AP3 KRSEAPWLG Obtained: 46.0 mg, 44%. HPLC: Rt- 5.24 min. [Found (ESI+) 1042.7592 
[M+H]+, C47H75N15O12 requires 1042.5792]. 
CP3[7azaW] KRSECP[7azaW]LG Obtained: 75.0 mg, 70.6%. HPLC: Rt- 4.48 min. [Found 
(ESI+) 1075.5450 [M+H]+, C46H74N16O12S requires 1075.5466]. 
HXNP1 GHSWPIAQGSATLFYGHG Obtained: 89.1 g, 27%. HPLC: Rt- 5.74 min. [Found (ESI+) 
965.4437 [M+2Na]2+, C87H121N25O23 requires 965.4442]. 
HXNP2 GHSWPIAQPGSATLFYGHG Obtained: 24.9 g, 14%. HPLC: Rt- 5.64 min. [Found 
(ESI+) 1000.9639 [M+2Na]2+, C90H126N26O24 requires 1000.9627]. 
ACP3[7azaW] ARSECP[7azaW]LG Obtained: 28.6 mg, 31%. HPLC: Rt- 4.13 min. [Found 
(ESI+) 1018.4906 [M+H]+, C43H67N15O12S requires 1018.4887]. 
RRRRRRR[Ahx]ACP3[7azaW] RRRRRRR[Ahx]ARSECP[7azaW]LG Obtained: 58.4 mg, 24%. 
HPLC: Rt- 4.42 min. [Found (ESI+) 742.4354 [M+3H]3+, C91H162N44O20S requires 742.4325]. 
 
2.3 Labelled peptides 
 
The succinimidyl esters of selected fluorophores were purchased from ThermoFisher 
Scientific. Conjugation to peptides were carried out according to manufacturer’s 
instructions as detailed below. 
 
2.3.1 AlexaFluor350-labelled CP6 (AF350-CP6) 
CP6 (2 eq, 2.5 mg, 2.5 µmol) was dissolved in NaHCO3 (0.5 mL, pH 8.3).  A solution of 
AlexaFluor350 (0.5 mg, 1.22 µmol) in DMSO (100 µL) was slowly added to the peptide 
solution. After 1 h, analytical HPLC showed complete disappearance of the dye (Rt = 5.44 
min) and new peaks at Rt = 6.28 min and Rt = 6.65 min. The reaction mixture was then 
applied to a C-18 solid phase extraction cartridge (Supelco) and was eluted with 
increasing amounts of acetonitrile in H2O (0.1% TFA): 0% acetonitrile, 20% acetonitrile, 
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40% acetonitrile, 60% acetonitrile, 80% acetonitrile, 100% acetonitrile. The eluted 
solutions were purified further by semi preparative HPLC and lyophilised to give AF350-
CP6 as a pale blue solid (0.4 mg, 25 %). HPLC: Rt- 6.29 min. [Found (ESI+) 1205.4215 
[M+H]+, C51H68N10O20S2 requires 1205.4126]. 
 
2.3.2 5-Carboxy-X-rhodamine-labelled ACP3[7azaW] (5-ROX-ACP3[7azaW]) 
ACP3[7azaW] (2 eq, 15.7 mg, 9.5 µmol) was dissolved in NaHCO3 (1.5 mL, pH 8.3).  A 
solution of 5-ROX (3 mg, 4.7 µmol) in DMSO (300 µL) was slowly added to the peptide 
solution. Immediately after mixing and performing analytical HPLC, a new peak appeared 
at Rt = 6.26 min. The mixture was then passed through a C-18 solid phase extraction 
cartridge (Supelco) and was eluted with increasing amounts of acetonitrile in H2O (0.1% 
TFA): 0% acetonitrile, 20% acetonitrile, 40% acetonitrile, 60% acetonitrile, 80% 
acetonitrile, 100% acetonitrile. The eluted solutions were purified further by semi- 
preparative HPLC and lyophilised to give 5-ROX-ACP3[7azaW] as a bright pink solid (2.4 
mg, 30.6 %). HPLC: Rt- 6.27 min. [Found (ESI+) 767.8521 [M+2H]2+, C76H95N17O16S requires 
767.8504]. 
 
2.3.3 5-Carboxy-X-rhodamine labelling of RRRRRRR[Ahx]ACP3[7azaW] (5-ROX-
RRRRRRR[Ahx]ACP3[7azaW]) 
RRRRRRRACP3[7azaW] (2 eq, 14.8 mg, 6.3 µmol) was dissolved in NaHCO3 (1.5 mL, pH 
8.3).  A solution of 5ROX (2 mg, 3.2 µmol) in DMSO (200 µl) was slowly added to the 
peptide in buffer. Immediately after mixing and performing analytical HPLC, a new peak 
appeared at Rt = 6.88 min. The mixture was then passed through a C-18 solid phase 
extraction cartridge (Supelco) and was eluted with increasing amounts of acetonitrile in 
H2O (0.1% TFA): 0% acetonitrile, 20% acetonitrile, 40% acetonitrile, 60% acetonitrile, 
80% acetonitrile, 100% acetonitrile. The eluted solutions were purified further by semi 
preparative HPLC and lyophilised to give 5-ROX-RRRRRRR[Ahx]ACP3[7azaW] as a bright 
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pink solid (0.6 mg, 5.3 %). HPLC: Rt- 5.97 min. [Found (ESI+) 549.1058 [M+5H]5+, 
C76H69N17O16S requires 549.1035]. 
 
2.4 UV-Visible absorption spectroscopy 
 
UV-Vis spectroscopy was performed using a Lambda 650 UV-Vis spectrophotometer 
(Perkin Elmer). Stock solutions of peptide were made at 10 mM in potassium phosphate 
buffer (PB) (10 mM, pH 7.0). For titration experiments, stock solutions of hemin were 
prepared at 5 mM in 30 mM NaOH in 10 mM PB, and PPIX stock solutions were prepared 
at 5 mM in DMSO. All stock solutions were stored at -20 °C and freshly thawed before 
use. 
Titrations were carried by a modification of the procedure of Kühl (Kühl et al. 2011) 
whereby increasing concentrations of hemin were added to 10 µM peptide in PB (10 
mM, pH 7.0). The titrant solution was prepared at 500 µM in PB with 10 µM peptide. The 
peptide concentration was kept constant and the following titrant:peptide ratios were 
used 0.025:1.0, 0.05:1.0, 0.075:1.0, 0.1:1.0, 0.2:1.0, 0.3:1.0, 0.4:1.0, 0.5:1.0, 0.75:1, 
1.0:1.0, 1.25:1.0, 1.5:1.0, 1.75:1.0, 2.0:1.0, 2.5:1.0. Kd values were calculated using the 
fitting program created by Thordarson in Matlab (Thordarson 2010). The program uses 
non-linear regression to fit the absorbances obtained to the equation: 
∆𝐴𝑜𝑏𝑠 =  𝜀∆𝐻𝐺{
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1
𝐾𝑎





+  4[𝐻0][𝐺0]} 
ΔAobs is the observed difference in absorbance units obtained by subtracting the 
absorbance of the guest (titrant) from the absorbance of the host (peptide)-guest 
(titrant) solution, which gives the absorbance of the host-guest complex. ε is the molar 
absorptivity coefficient of the host-guest complex. H is the concentration of peptide, G 
is the titrant concentration. Ka is the association constant. Kd = 1/Ka. 
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2.5 Fluorescence spectroscopy 
 
Fluorescence spectroscopy was performed using a Lambda 55 Fluorescence 
spectrometer (Perkin Elmer). For titration experiments, increasing concentrations of 
hemin were added to 10 µM peptide in PB (10 mM, pH 7.0) as for the UV-visible 
experiments. The titrant solution was prepared at 500 µM in PB with 10 µM peptide. The 
peptide concentration was kept constant and the following titrant:peptide ratios were 
used: 0.025:1.0, 0.05:1.0, 0.075:1.0, 0.1:1.0, 0.2:1.0, 0.3:1.0, 0.4:1.0, 0.5:1.0, 0.75:1, 
1.0:1.0, 1.25:1.0, 1.5:1.0, 1.75:1.0, 2.0:1.0, 2.5:1.0. Kd values were calculated using the 
fitting program created by Thordarson in Matlab (Thordarson 2010) to fit the emission 
data to the equation: 
∆𝐹𝑜𝑏𝑠 =  𝑘{
1
2
(𝐺0 + 𝐻0 +  
1
𝐾𝑎





+  4[𝐻0][𝐺0]} 
ΔFobs is the observed fluorescence unit obtained by subtracting the fluorescence of each 
guest (hemin) concentration from the fluorescence of the host (peptide) only. [H] is the 
concentration of peptide, [G] is the titrant concentration. Ka is the association constant. 
Kd = 1/Ka. 
 
2.6 Circular Dichroism spectroscopy 
 
Circular dichroism spectroscopy was performed on a Chirascan CD spectrometer 
(Applied Photophysics Ltd.). Far-UV CD spectra were recorded between 195 and 300 nm 
at 21 °C. Peptides were at 5 µM in phosphate buffer (10 mM, pH 7.0), or methanol.  The 




2.7 Protein modelling and sequence alignment 
 
Protein structures were visualised and images created using the PyMOL Molecular 
Graphics System, Schrödinger, LLC. (https://pymol.org/). Sequence alignments were 
performed using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) with 
reviewed sequences from the UniProtKB database (http://www.uniprot.org/uniprot/). 
 
2.8 Nuclear magnetic resonance spectroscopy 
 
1H NMR spectra were recorded on a Bruker Avance 500 MHz spectrometer at 298 K. 1H 
chemical shifts are referenced to tetramethylsilane (TMS) and expressed in ppm. 
Peptides were dissolved in DMSO-d6. Regions of relevant proton resonances were 
identified by using standard 1H COSY (cosygpqf) pulse sequences outlined within the 
Bruker library. 
 
2.9 Cell culture 
 
FEK-4 human skin fibroblasts were cultured in Eagle’s Minimum Essential Medium with 
Earle’s salts and sodium bicarbonate (Sigma), supplemented with 2 mM L-glutamine 
(Invitrogen), 50 U/mL penicillin (Invitrogen) and 50 μg/mL streptomycin and 15% FBS 
(Sigma). FBS was heat-inactivated at 56 °C for 1 h before adding to media. Cells were 
maintained at 37 °C under 5% CO2 in a humidified incubator. 
Cells were subcultured on reaching 70-80% confluency. After washing with PBS, cells 
were incubated at 37 °C for 5 min with 0.25% trypsin. Detached cells were then collected 
with media and centrifuged at 200 g for 5 min. The supernatant was discarded and the 
cell pellet resuspended in fresh media. 
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HEK 293F cells (Invitrogen) were cultured in unsupplemented FreeStyle™ 293 Expression 
Medium. Cells were maintained at 37 °C under 5% CO2 in a humidified incubator. Cells 
were subcultured on reaching between 1 × 106 –3 × 106 viable cells/mL by dilution of a 
sample of the growing culture in fresh medium.  
For cell counting, a cell suspension was mixed 1:1 with trypan blue (Sigma) and 10 µL 
was used in a Neubauer-improved hemocytometer 
For storage, 1x106 cells were re-suspended in 50% media/40% FBS/10% DMSO, v/v/v 
and placed in liquid nitrogen. Cells were thawed by placing in a water bath at 37 °C until 
the last ice crystal had just dissolved, and then they were added to a larger volume of 
media for centrifugation at 200 g for 5 min. The supernatant was discarded and the cell 
pellet re-suspended in fresh media for culture. 
 
2.10 Treatment with hemin 
 
Cells were treated with hemin by direct addition of hemin stock solution to the cellular 
growth medium to reach a final concentration of 10 µM. Cells were then returned to 
incubation at 37 °C, 5% CO2 for 18 h and protected from light during all subsequent use. 
 
2.11 Treatment with UVA 
 
A broad-spectrum 4 kW UVA lamp (Sellas, Germany) was used as a source of UVA 
radiation throughout this study. The irradiation times for corresponding UVA doses were 
calculated by measuring the fluence using a calibrated IL1700 radiometer (International 
Light, Newbury, MA). Cells were seeded in dishes for irradiation and the media was 
aspirated. Cells were washed with PBS, and then fresh PBS was added prior to UVA 
irradiation. The cells were irradiated at a dose of 250 kJ/m2. Irradiation was conducted 
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in a dark room with air-conditioning set to 18°C in order to prevent overheating by the 
UVA source. Following UVA irradiation, cells were removed to ice and then used 
immediately. 
 
2.12 Cell lysis 
 
Following treatment with either hemin or UVA, cells were detached with 0.25% trypsin 
and the pellet was collected by centrifugation at for 5 min. The supernatant was 
discarded and the cell pellets were suspended in 0.5 mL lysis buffer (KH2PO4, 20 mM; 
ethylene-diaminetetraacetic acid (EDTA), 0.5 mM; PMSF, 0.1%; with a complete Mini 
EDTA-free protease inhibitor cocktail tablet (Roche)), and then lysed by sonication for 14 
seconds on ice (Rapidis 300, Ultrasonics, UK). After sonication, cell lysates were 
centrifuged at 8 500 g for 5 min at 4 °C (Biofuge 13, Heraeus instrument). The 
supernatant containing the total protein was then collected and stored at -80 °C for 
future use. 
 
2.13 Quantification of protein concentration in cell lysates 
 
Quantification of protein levels in cell lysates was performed using the Pierce BCA 
Protein Assay (ThermoFisher Scientific). The assay was carried out according to the 
manufacturer’s protocol. A standard curve was constructed using BSA of final 
concentrations 2000, 1500, 1000, 750, 500, 2250, 125, 25, 0 µg/mL. Absorbance was 







2.14 MTT assay 
 
Cells were plated (7 × 104 cells/mL) in 96-well plates and left for 48 h to adhere fully 
before addition of CP3[7azaW] for 48 h at 37 ˚C. Concentrations used were 250 µM, 100 
µM, 50 µM, 10 µM, 1 µM, 0.5 µM, 0.1 µM, 1 nM in standard media for cell growth (1% 
DMSO, 10% FBS in RPMI). After 48 h, cells were washed three times with PBS and 100 
µL of MTT reagent was added (0.5 mg/mL, 10% PBS:medium) and incubated for 2 h 
protected from light. Following aspiration of the MTT reagent, 100 µL of DMSO was 
added and the plates were shaken for 2 min. Absorbance was measured using a Fluostar 
Omega (BMGLabTech) plate reader at 570 nm with 630 nm as the reference wavelength. 
The results obtained from the analysis above were averaged for each concentration and 
then normalised to the untreated cells. These were then plotted as % cell viability against 
normalised controls. Normalised standard deviations were also calculated and displayed 
as error bars on the graphs generated. 
 
2.15 Fluorescence microscopy  
 
Peptide uptake: FEK-4 were seeded on glass coverslips at a density of 6x104 per 3 cm dish 
to reach 70-80% confluence. Peptides were prepared at 1 µM or 10 µM in fresh media 
or PBS. Cells were washed with PBS and incubated with the fresh peptide solutions, or 
media or PBS alone, for 30 min or 60 min at 37 °C in the dark. After this treatment, the 
cells were washed with PBS and fixed with 4% paraformaldehyde in PBS for 15 min at 
room temperature. After washing again with PBS, the cells were permeabilised with 
Triton X-100 and stained with 600 nM DAPI at room temperature for 20 min in the dark. 
The coverslips were then removed from each dish and mounted on glass slides with 
fluorescence mounting medium (DAKO), and then left to dry at room temperature 
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overnight in the dark. The slides were then imaged with a LSM 510 META (Zeiss) confocal 
laser scanning microscope.  
 
Bach1-GFP expressing cells: Transfected cells were collected by centrifugation of 
growing culture at 200 g for 5 min. Cells were then resuspended in PBS at 2x106 cells/mL 
and fixed by addition of 4% paraformaldehyde in PBS and incubation at room 
temperature for 10 min. 200 µL was then pipetted onto a coverslip and adhered by 
centrifugation at 550 g for 5 min. The coverslips were gently washed with PBS and then 
covered in 600 nM DAPI and incubated at room temperature for 20 min in the dark. The 
coverslips were then washed gently three times with PBS and mounted on glass slides 
with fluorescence mounting medium (DAKO), and then left to dry at room temperature 
overnight in the dark. The slides were then imaged with a LSM 510 META (Zeiss) confocal 




Transfection was carried out by the protocol of Portolano et al., 2014. HEK 293F cells 
were subcultured at least 5 times before transfection. Cells were subcultured at a density 
of 0.5x106 24 h before transfection. 3 µg of plasmid DNA per 1x106 cells to be transfected 
was added to PBS followed by 0.6 mg PEI. The mixture was then incubated at room 
temperature for 20 min and added to the cells. The cells were cultured for a further 48 






2.17 Protein purification 
 
The frozen cell pellet was defrosted into 40 mL lysis buffer (100 mM potassium acetate, 
50 mM Tris pH 7.5, 5% glycerol, 0.3% Triton X-100, protease inhibitors) per L of culture 
and suspended through a combination of pipetting and homgenisation. Cells were lysed 
by sonication - 15 seconds on followed by 15 seconds off, repeated 3 times. The lysate 
was then centrifuged at 30 000 g for 25 min at 4 °C (Beckman J2 MC) to remove cellular 
debris, and the supernatant retained. 1.25 mL of anti-FLAG packed agarose resin (Sigma) 
per L of culture was equilibrated with resin equilibration buffer (100 mM potassium 
acetate, 50 mM Tris pH 7.5) by washing 3 times. The cell lysate was then incubated with 
the affinity gel for 90 min at 4 °C with gentle agitation. The resin was then washed with 
45 mL of pre-chilled buffer 1 (100 mM potassium acetate, 50 mM Tris pH 7.5, 5% glycerol, 
0.3% Triton X-100) and centrifuged at 550 g for 1 min. This was repeated with high salt 
buffer (300 mM potassium acetate, 50 mM Tris pH 7.5, 5% glycerol), followed by low salt 
buffer (50 mM potassium acetate, 50 mM Tris pH 7.5, 5% glycerol) and Enterokinase 
Cleavage Buffer (500 mM Tris, 2mM CaCl2, pH 8.0, 1% TWEEN 20). The resin was then 
resuspended in Enterokinase Cleavage Buffer and 0.04 U of enterokinase (Sigma) was 
added. The tube atmosphere was replaced with N2 gas and the sample was incubated 
overnight at 4 °C with gentle agitation. The sample was centrifuged at 550 g for 10 min 
then the resin was separated from the cleaved protein. The sample was concentrated by 
use of a centrifugal filter with a 50 kDa cut off (Millipore). 
 
2.18 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
 A resolving gel was prepared using a 10% resolving polyacrylamide gel solution (10% 
acrylamide/bis-acrylamide, 0.5 M Tris-HCL pH=6.8, 10% SDS, 10 µL N,N,N',N'-
tetramethylethylenediamine (TEMED) and 0.03 % ammonium persulfate (APS)). The gel 
solution was poured into an empty BioRad gel casting system, and then it was allowed 
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to form at room temperature for 1 h. H2O was layered on top of the resolving gel in order 
to prevent evaporation. The stacking gel solution was prepared using a 4% 
polyacrylamide gel (4% bis-acrylamide, 1.5M Tris-HCL, pH=8.8, 10% SDS, 5 µL TEMED and 
10% APS. The water was removed from the top of the resolving gel and replaced with 
the stacking gel which was allowed to set at room temperature for a further 45 min. 
Protein samples were diluted in a 5x loading buffer (300 mM Tris, 50% glycerol, 10% 
sodium dodecyl sulfate (SDS), 0.5% bromophenol blue) and loaded into the SDS 
polyacrylamide gel. Electrophoresis was performed in running buffer (25mM Tris-HCl, 
200mM Glycine, 0.1% w/v SDS) subjected to 150 V for 1 h. 
 
2.19 Coomassie staining 
 
For Coomassie staining, the gel was fixed in 50% methanol, 10% acetic acid (v/v) in H2O 
overnight at room temperature with gentle agitation. It was then stained with 0.25% 
Coomassie R-250 (w/v) in fresh fixing solution for 2 h at room temperature with gentle 
agitation. It was then destained to remove excess stain in 5% methanol, 7.5% acetic acid 
(v/v) in H2O at room temperature with gentle agitation for 4 h. The destain solution was 
replaced every hour until clear blue bands were observed on the gel. 
 
2.20 Western blotting 
 
For Western blotting, the protein was transferred from the SDS polyacrylamide gel to a 
PVDF membrane (Immobilon-P, Millipore) by using a tank blotting unit filled with 
transfer buffer (3 % w/v tris, 14.4 % w/v glycine, 20 % methanol) subjected to 14 V 
overnight at 4 °C. Membranes were then incubated with 3% BSA in TBS (20 mM Tris-HCl, 
0.15 M NaCl, pH 7.5) to block nonspecific binding at room temperature for 1 h. 
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Monoclonal ANTI-FLAG M2 antibody produced in mouse, was used at a 1:1,000 dilution 
in 3% BSA/TBS (w/v) and incubated with the membrane for 30 min at room temperature 
with gentle agitation, following manufacturer’s instructions. The membrane was then 
washed 3 times with 3% BSA/0.1% Tween 20/TBS (w/v/v). The secondary antibody 
IRDye® 800CW Donkey anti-Mouse IgG (LI-COR) was diluted 1:10,000 in 3% BSA/0.1% 
Tween 20/TBS (w/v/v) and incubated with the membrane for 1 h at room temperature 
with gentle agitation. The membrane was then washed 3 times with 3% BSA/0.1% Tween 












3 Synthesis of peptide probes based on the amino acid sequence 





As outlined earlier, a heme sensor needs two main components: a probe and a reporter. 
The role of the probe is to bind heme and orient it correctly for energy transfer to the 
sensor if the reporter is a fluorophore. Peptides are good candidates for heme ligands 
because they are easily synthesised and can potentially be engineered to bind heme with 
good affinities. The binding of hemin to a peptide probe then needs to be transferred 
into a measurable signal. Using a fluorophore to transduce this signal is attractive, firstly 
because of the absorbance characteristics of heme and secondly because it would allow 
the direct and rapid conversion of binding to a detectable signal. Fluorescence is a 
simple, highly sensitive and generally inexpensive, quantifiable analytical technique. A 
fluorophore can be conjugated to a peptide so that a single unit contains both the 
molecular recognition unit and the signal generator. 
 
3.1.1 Designing the probe unit 
 
Heme b can participate in non-covalent, reversible interactions with proteins through 
the amino acid side chains of Cys, His, Tyr, Met and Lys residues coordinating the iron of 
heme. Analysis of the structure of 125 heme-binding proteins from the Protein Data 
Bank shows that the majority (80%) of heme binding involves His (Li et al. 2011). 
However, there are several important proteins that interact with heme through a Cys 
residue. For instance, HAP1 is a yeast transcriptional activator and was the first DNA 
binding protein to be found to be regulated by transient binding of heme. Much like 
Bach1 it forms a complex via its heme binding domain that represses transcription when 
bound to DNA. The addition of heme causes dissociation of the repressor and HAP1 can 
then promote transcription (Zhang and Guarente 1994). The HAP1 heme-binding 
domain contains six repeats of the amino acid sequence Lys/Arg-Cys-Pro-Val-Ile-Asp-His 
within a stretch of 200 amino acids. It was noted that this sequence was very similar to 
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that found in two other proteins that are regulated by heme: the enzyme ALAS and the 
kinase heme regulated eukaryotic initiation factor 2α kinase (HRI). The sequence was 
found to be necessary in ALAS for its repression by heme and thus the importance of the 
Cys-Pro motif in heme binding and regulation of protein function was realised. The heme 
binding sequences of other proteins such as globins and cytochromes differ from this 
‘heme regulatory motif’ (HRM) in that they are based on double coordination of the 
heme by either a His and a Met or two His residues and are known to bind heme almost 
irreversibly and sometimes covalently (Phillips 1980; Aoyama et al. 1995; Dawson 1988). 
In contrast, it was hypothesised that instead the Cys-Pro HRMs allow reversible binding 
by heme to modulate protein function.  
 
Synthesis of a decapeptide based on the sequence of the HRM from HAP1 (Ala-Lys-Arg-
Cys-Pro-Val-Asp-His-Thr-Met) revealed that this sequence bound heme resulting in a 26 
nm shift of the Soret band (from 388 to 362 nm) of heme to a shorter wavelength on 
addition of equimolar hemin (Zhang and Guarente 1995). A cysteine to alanine mutation 
abolished heme binding and a proline to alanine mutation greatly reduced heme binding 
showing that the peptide binds heme through the cysteine residue and the proline aids 
the interaction. 
 
A combinatorial peptide library of nonapeptides was screened for heme binding in an 
attempt to identify the general features of such heme binding sequences (Kühl et al. 
2011). A library of the sequence X4[C/H/Y]X4 was screened with hemin and yielded 180 
peptides that bound heme that were further analysed for sequence features. Of the 
sequences analysed, 38.4% contained His, 40.0% contained a Tyr and 21.2% contained a 
Cys. In general, high proportions of polar and charged amino acids were found with Ala, 
Gly, Phe, Tyr, Lys, Arg, Glu, Asp and Gln being prevalent N-terminal to the central heme-
coordinating residue. High numbers of Ala, Val, Phe, Ser, Lys, Arg, Asp and Asn residues 
were observed towards the C-terminus. Leu Thr, His and Asn were more frequently 
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found on the N-terminal side of peptides with His or Tyr as the central heme binding 
residue compared to peptides with Cys as the central heme binding residue. Cys 
containing peptides were much more likely however, to have a proline at Cys+1 or Cys+2 
whereas Glu was never found in the four residues after the Cys. In 55.6% of the 
sequences, as well as the heme coordinating His/Tyr/Cys, an additional His or Tyr was 
present. These findings were characteristics of sequences of the heme binding sites in 
many proteins, for example HAP1, IRP2 and catalase. 
 
Further to this study, investigations were carried out on 22 9-mer Cys containing 
peptides some of which were based on the sequences of known heme-regulated 
proteins (Kühl et al. 2013). Of these peptides, 10 contained only a Cys and the other 12 
a Cys followed by a Pro. Titration of increasing amounts of hemin to the peptides and 
subtraction of the spectra of heme alone showed that different peptides gave spectra 
that could be categorised into four groups (Figure 3.1). The first group contained only 
five cysteine-only peptides and their spectra were characterised by a minimum around 
370 nm followed by a maximum at 420 nm. The second group, containing four CP 
peptides and one cysteine-only peptide had a peak at around 370 nm. The third 
contained two cysteine-only and two CP peptides and was characterised by maxima at 
both 370 and 420 nm. The fourth contained the control peptide AAACAAA as well as one 
other CP peptide and had a much shallower, broader maximum at 400 nm (Figure 3.1). 
It was found that it was only Cys-only peptides that were found in group 1, while group 
2 was predominantly Cys-Pro peptides. Group 3 had 2 Cys only peptides and 2 Cys-Pro 
peptides. There was a lack of negatively charged amino acids to the C-terminal side of 
the Cys residue but there seems to be less importance on the N-terminal side. In the 
peptides that lacked a positively charged residue, there was a hydrophobic residue to 
the C-terminal side of the Cys residue. The peptides with the lowest Kds (<1 µM) were 
those with the motif C-X/P-H/F. The next range of Kds (1.37 µM – 6.43 µM) were from 
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peptides that had non-polar, non-aromatic amino acids (Ala, Ile, Leu, Nle, Val) at C-
terminal positions or a Trp. 
 
 
Figure 3.1. Difference absorbance spectra of cysteine containing peptides from (Kühl et al. 2013). 
 
Analysis of the X-ray crystallographic structures of 18 heme binding proteins revealed 
the sequence GX[H/R]XC[P/L/A/V]G as a motif for heme binding (Li et al. 2011). Of the 
18 proteins with cysteine as the heme coordinating residue, 6 were followed by a 
proline, while the others were always followed by hydrophobic amino acids: leucine, 
alanine, valine and isoleucine. The -2 position favoured a histidine or an arginine to 
interact electrostatically with the heme propionate units while the following small 
glycine residue aided flexibility. In the 6 protein structures with CP motifs, the proline 
introduces a bend for the following peptide chain away from the face of the heme. 
However, further downstream there were slight differences. In chloroperoxidase (PDB 
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ID 2CIW), Rev-erb (3CQV) and microsomal prostaglandin E synthase (2PBJ) where the 
proline is highly conserved the α-helices that follow align nearly perpendicularly to the 
heme plane whereas in the P450 family where the proline is less conserved the α-helices 
that follow align in parallel to the heme plane. It is possible therefore that when the 
proline is conserved the structure it creates is necessary for function. Indeed the proline 
following Cys409 in HRI is essential for heme binding (Igarashi et al. 2008). However, 
with so few crystal structures available for proteins that bind heme through the Cys-Pro 
motif it is difficult to assess the full functionality of temporary heme binding pockets.  
Bach1 contains six Cys-Pro motifs with the sequences shown in Table 3.1. Mutagenesis 
studies suggest that the first two Cys-Pro motifs do not bind heme (Suzuki et al. 2004). 
A Bach1 fragment including amino acids 417- 739 (including the last 4 Cys-Pro motifs) 
appeared to bind to 4 or 5 hemin molecules, which was the same as a fragment of amino 
acids from 174-739 (including all 6 Cys-Pro motifs) (Hira et al. 2007). Mutation of each 
of the cysteines of CP3-CP6 to an alanine reduced the hemin binding capacity of Bach1 
by 1 equivalent indicating that each can bind one molecule of heme.  
 
Motif Amino acid sequence Cysteine position 
CP1 LPSLCPKYR 224 
CP2 PASQCPTEKS 301 
CP3 KRSECPWLG 438 
CP4 SSVNCPFIS 464 
CP5 QQEPCPYAC 495 
CP6 SAADCPLSF 649 




The Bach1 peptides are all Cys-Pro peptides and so are expected to have difference 
spectra like group 1 and 2. The only Bach1 peptide that has a negative residue C-term to 
the Cys is CP2 but CP3 and CP5 have glutamic acids to the N-terminal side. CP1 and CP2 
both have positive amino acids C-term to the Cys, whereas the others have large 
hydrophobic residues immediately after the Pro. CP4, CP5 and CP6 however, do have a 
polar residue (Ser or Cys) following that. 
 
3.2 Synthesis of peptides based on protein CP motifs 
 
Based on previous reports showing that small peptides can bind to heme with good 
affinities (Kühl et al. 2013) and the interest of this work in the Bach1/HO-1 system, the 
first potential heme-binding peptides synthesised in this work were based on the Cys-
Pro motifs of Bach1 known to bind to hemin – CP3-CP6 (Table 3.1.). A peptide, based on 
the Cys-Pro motif of IRP2 (Kühl et al. 2013) was included as a positive control as was the 
negative control KRSEAPWLG [AP3], in which the heme binding cysteine is changed to 
alanine. 
 
CP3 was synthesised on Rink Amide MBHA resin on a 0.6 mmol scale using Fmoc solid 
phase peptide synthesis (Palomo 2014). The first amino acid, Fmoc-Gly-OH (4 eq) was 
coupled manually using PyBOP (4 eq) as the activating agent and DIEA (6 eq) as the base 
(Scheme 3.1). The first amino acids of CP4, CP6 and AP3 were coupled analogously. IRP-
2 and CP5 were synthesised on Wang resin. The first amino acid was coupled manually 
using 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT) (4 eq) as the activating 
agent and 1-methylimidazole (2 eq) as the base (Harth-Fritschy and Cantacuzene 1997).  
After coupling of each first amino acid, the acylated resin was then transferred to an 
Activotec automated peptide synthesiser for the coupling of the remaining amino acids 
(3 eq) using PyBOP (3 eq) and DIEA (6 eq). Removal of the Fmoc group in each cycle was 
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effected by 25% piperidine in DMF. Final cleavage from the resin and full side-chain 
deprotection was achieved using TFA/TIS/H2O/EDT (92.5:2.5:2.5,2.5, v/v/v/v). Each 
peptide was purified by RP-HPLC to >98% purity, which was confirmed by analytical 
HPLC. The identity of each peptide was confirmed by ESI-MS. 
 
CP5 was synthesised on Wang resin with MSNT as Cys was the first residue to be coupled 
and this method reportedly gives a better coupling efficiency with low racemisation 
when using Cys resides (Harth-Fritschy and Cantacuzene 1997). After purification of CP5, 
two closely running peaks were seen in the analytical HPLC. It was suspected that this 
resulted from intramolecular disulfide bond formation involving the two Cys residues 
upon resin cleavage. Further treatment with EDT converted the double peak to a single 
species whose MS was consistent with the peptide structure. 
 







Table 3.2. Synthesis of CP peptides derived from Bach1 and IRP2 
 
 
Peptide Amino acid sequence Yield (%) 
CP3 KRSECPWLG 28 
CP4 SSVNCPFIS 35 
CP5 QQEPCPYAC 67 
CP6 SAADCPLSF 36 
CP-IRP2 TPILCPFHL 43 





Scheme 3.1. Synthesis of CP3. Reagents and conditions: a. Piperidine/DMF (1:5 v/v), 2 + 5 min b. 
Fmoc-Gly-OH, DIEA, PyBOP, DMF, RT, 1 h; c. Piperidine/DMF (1:4 v/v), 5 + 10 min; d. Fmoc SPPS: 
Fmoc-AA-OH, PyBOP, DIEA, DMF; e. TFA/TIS/H2O/EDT (92.5:2.5:2.5:2.5, v/v/v/v), 3 h. 
 




Scheme 3.2. Synthesis of CP-IRP2. Reagents and conditions: a. Fmoc-Gly-OH, 1-methylimidazole, 
MSNT, DCM, RT, 16 h; c. Piperidine/DMF (1:5 v/v), 5 + 10 min; d. Fmoc SPPS: Fmoc-AA-OH, 
PyBOP, DIEA, DMF; e. TFA/TIS/H2O/EDT (92.5:2.5:2.5:2.5, v/v/v/v), 3 h. 




























































































































3.3 Hemin binding to CP peptides 
 
UV-Vis spectroscopy can be used to monitor the binding of heme to peptides (Kühl et al. 
2011). The Soret band of heme represents the π-π* transition associated with the 
porphyrin ring but when heme binds to a peptide, interaction of the peptide with the 
porphyrin ring increases the energy gap of this transition and leads to a blue shift of the 
Soret band in the UV-Vis spectrum.  
Increasing amounts of hemin (0.25 μM – 25 μM) were titrated against a fixed amount of 
peptide (10 μM) in PB (10 mM, pH 7.0) and the UV-Vis spectrum was measured for each 
concentration between 250 nm and 600 nm (Figure 3.3. A). A spectrum of only hemin at 
each concentration was also measured. The difference spectra representing only hemin 
bound to peptides were created by subtracting the spectra of hemin alone from the 
spectra of peptide with hemin (Figure 3.3. B, D, F, H, J, L). The Soret band of 10 μM hemin 
in phosphate buffer (pH 7.0) was observed at 387 nm.  
Kühl et al. identified two features (either maxima or minima) that could be present in 
the difference spectra of their Cys peptides, one around 420 nm which they designated 
the Soret peak and one around 365 nm that they designated the near UV band. Most of 
the CP peptides tested here have well defined features in the near UV region. The hemin-
bound complexes of CP4, CP5, CP6 and CP-IRP2, have peaks at 367 nm. CP5 and CP6 also 
have second smaller Soret peaks at 419 and 421 nm respectively which puts them into 
the third category found by Kühl et al. (2013). CP4 and CP-IRP2 do not have such well-
defined Soret peaks and therefore fit better into Kühl’s second group. The difference 
spectra of CP3 with hemin has two troughs, one at 340 nm in the near UV and one at 
397 nm for the Soret band; this pattern is unlike any of the previously identified groups. 
The AP3 peptide without the cysteine residue for coordination of the heme iron atom 
has a spectrum slightly similar to Kühl’s group one with a minima at 347 nm followed by 
a peak at 420 nm. However, these features are less well defined compared to the Cys 
containing peptides. Once the difference spectra were plotted and the new wavelengths 
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of the Soret peaks identified, the ΔAbsorbance at these wavelengths was plotted against 
the hemin concentration (Figure 3.3. C, E, G, I, K, M.)  These graphs for the CP peptides 
show a steady increase or decrease in ΔAbsorbance representing heme binding until 
they start to plateau when the binding sites of the peptide are saturated. For heme 
binding to the AP3 peptide, the plot is much flatter, consistent with the loss of Cys-
mediated binding. This data were used to calculate a Kd by fitting to the one-site binding 
equation (Thordarson 2010). 
 
∆𝐴𝑜𝑏𝑠 =  𝜀∆𝐻𝐺{
1
2
(𝐺0 + 𝐻0 +  
1
𝐾𝑎





+  4[𝐻0][𝐺0]} 
 
This equation is widely used to find dissociation constants for ‘host-guest’ interactions, 
including by Kühl et al. (2013) to quantify heme binding to peptides. Fitting data is 




































































































































Figure 3.3. UV-Vis spectroscopy of CP peptides with hemin. Peptide concentration was constant 
(10 μM) whilst hemin was titrated (0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 
7.5 μM, 10 μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 25 μM) in phosphate buffer (10 mM). After 2 
min stirring the absorbance was read between 250 nm and 650 nm. Error bars show the 
standard deviation (n=3). A) Absorbance of CP3 with increasing amounts of hemin. B) Difference 
spectrum of CP3 with hemin. C) ΔAbsorbance of CP3 with hemin at 397 nm against hemin 
concentration. D) CP4. E) 367 nm. F) CP5. G) 367 nm. H) CP6. I) 367 nm. J) CP-IRP2. K) 367 nm. 
L) AP3. M) 347 nm. 








































































































The peak wavelengths for the synthesised CP peptides along with the corresponding 
calculated Kds are reported in Table 3.3. Table 3.3. Peak wavelengths of CP peptides and the 
corresponding calculated dissociation constants.The Kds reported by Kühl et al. range from 
0.28 µM to 48.8 µM. The CP peptides tested here have Kds ranging from 0.26 µM to 33.9 
µM which are quite comparable. Kühl et al. studied and reported CP-IRP2 peptide Kds of 
0.60 ± 0.41 µM for the near UV band and 2.03 ± 1.38 µM for the Soret band and here 
the Kds were found to be 0.89 ± 0.16 µM and 20.2 ± 4.6 µM so while the Kd for the near 
UV band matches well, the Soret band Kd was found to be 10-fold higher here. CP6 was 
found to have the lowest Kd of 0.26 ± 0.24 µM. The ΔAbsorbance data of CP5 could not 
be fitted to the binding equation and a Kd value could not be obtained. This could be due 
to the presence of two Cys residues which could be allowing more complicated peptide-
heme structures to form and thus confounding the data. CP5 also has two Pro residues 
which could contribute to a conformation that does not favour strong heme binding 
compared to the other Bach1 derived peptides.  
 
CP4 has the C-X/P-H/F motif identified by Kühl et al. as the best predictor for a low Kd. 
However, here CP4 has the highest Kd of the CP peptides tested. CP3 with only the 
hydrophobic WLG sequence C-terminal to the Cys residue and the two positive residues 
Lys and Arg at the N-terminus would also be predicted to have a low micromolar Kd based 
on the patterns observed by Kühl et al. This is indeed the case with a Kd of 1.7 µM 
calculated for the Soret band with CP3. CP6 which does not have any positively charged 



















CP3 340 - - 397 1.7 1.0 
CP4 367 33.9 11.1 - - - 
CP5 367 - - 419 - - 
CP6 367 0.26 0.24 421 - - 
IRP2 367 0.89 0.16 418 20.2 4.6 
AP3 347 - - 420 - - 
Table 3.3. Peak wavelengths of CP peptides and the corresponding calculated dissociation 
constants. 
 
Although there appears to be some unspecific binding of hemin to the AP3 peptide, 
presumably via hydrophobic interactions with the porphyrin ring and electrostatic 
interactions between the hemin propionates and the positively charged side chains of 
the peptide, the ΔAbsorbance data could not be fitted to the binding equation and a Kd 
value could not be obtained. As the plot of ΔAbsorbance against hemin concentration 
also remains very flat this suggests that the binding sites of the peptide are not being 
saturated. Taken together this is consistent with relatively little binding occurring 
between the peptide and hemin which highlights the importance of the Cys residue for 
effective hemin binding. Even though AP3 also contains a Lys and an Arg residue which 








3.4 PPIX binding to CP3  
 
PPIX is the immediate precursor to heme in the cellular heme biosynthetic pathway and 
consists of the same porphyrin structure without the central iron. Therefore, this 
molecule will be present in cells as well as hemin itself. The absorbance spectrum of PPIX 
is quite similar to that of hemin with an intense Soret band at 400 nm. As the aim of the 
work was to measure cellular heme concentration, any binding of PPIX to the peptide 
could give a false positive signal and therefore misrepresent the amount of heme 
present in the cell. It was therefore important to test the interaction of PPIX with the 
peptides to ensure that minimal binding occurred. A titration was carried out with PPIX 
as with hemin previously. While the concentration of CP3 peptide was constant (10 µM) 
in PB, pH 7.0, PPIX concentration was increased from 0.25 µM to 25 µM and the 
absorbance of each solution measured between 250 nm and 600 nm (Figure 3.4.).  
 
The difference absorbance spectrum of CP3 with PPIX has a similar shape to the 
difference absorbance spectrum of CP3 with hemin, both having two minima. The 
wavelengths of the two minima for PPIX binding are 342 nm and 456 nm, 342 nm being 
very close to the 340 nm of hemin binding, while the 456 nm trough is red shifted 59 nm 
compared to the 397 nm Soret band of CP3 with hemin. The plot of ΔAbsorbance at 342 
nm against PPIX concentration shows very little binding until a 10 µM PPIX concentration 
(equivalent to a 1:1 ratio of peptide:PPIX). The data again could not be fitted to the one 
site binding equation. The lack of binding of PPIX to CP3 is thus consistent with the lack 
of iron in PPIX to mediate binding through the Cys in CP3. From this it can be 






















































Figure 3.4. UV-Vis spectroscopy of CP3 with PPIX. Peptide concentration was constant (10 μM) 
whilst PPIX was titrated (0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 7.5 μM, 10 
μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 25 μM) in phosphate buffer (10 mM). After 2 min stirring 
the absorbance was read between 250 nm and 650 nm. Error bars show the standard deviation 
n=3. A) Absorbance of CP3 with increasing amounts of PPIX. B) Difference spectrum of CP3 with 
PPIX. C) ΔAbsorbance of CP3 with PPIX at 420 nm against hemin concentration. 
 
3.5 Confirming binding stoichiometry of hemin to CP peptides 
 
Given the structures of the peptides, a 1:1 binding model with heme was expected and 
indeed the data from the difference spectra did not fit to either a 2:1 or 1:2 binding 
model (Thordarson 2010). However, to confirm that a 1:1 model was the correct one to 
use to determine the dissociation constant, the method of continuous variation was 
employed which has been used previously for determining the stoichiometry of hemin 
binding to various other synthetic peptides (Mahajan and Bhattacharjya 2013). The total 
molar concentration of peptide and heme was kept constant while varying the mole 
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fraction. The maximum on the plot corresponds to the binding stoichiometry. The Job 










3.6 Attachment of a fluorophore to the N-terminus of CP6 
 
In order to monitor heme binding to a peptide probe, a suitable reporter unit needs to 
be attached. Attachment of 3 different fluorophores to recombinant HO-1 has previously 
been shown to result in fluorescence quenching upon heme binding (Koga et al. 2013). 
The fluorophores used were AlexaFluor 350 and 2-anilinonaphthalene-6-sulfonic acid 
which have emission bands which overlap with the Soret band of hemin, and AlexaFluor 
555 which has an emission band that overlaps with the α- and β- absorption bands of 
hemin at 574 nm and 553 nm respectively (Blank et al. 2001).  The HO-1-AlexaFluor350 
conjugate exhibited reduced fluorescence in proportion to the amount of hemin present 
and was almost completely quenched on addition of equimolar and higher amounts of 















Figure 3.5. Job plot of hemin with CP-IRP2. Total molar concentration of peptide and hemin (10 
µM) was constant while the mole fraction of each component was varied in PB (10 mM, pH 7). 
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hemin. The HO-1-AlexaFluor350 conjugate has a lower dissociation constant and 
therefore higher affinity for hemin. As such, AlexaFluor 350 was deemed the best 
fluorophore to use with the most efficient energy transfer and with less disruption of 
the binding pocket.  
AlexaFluor 350 was therefore chosen as the fluorophore to conjugate to a CP peptide to 
act as a reporter. CP6 was the peptide with the lowest Kd for hemin and was therefore 
chosen as the lead peptide. The fluorophore, as a N-hydroxy-succinimidyl ester, was 
reacted with the free peptide at room temperature for 1 hour in NaHCO3 buffer at pH 
8.3, protected from light. As the dye is expensive and less available than the peptide, the 
peptide was used in excess (2 eq) to ensure complete consumption of the dye. The 
reaction was monitored by HPLC which showed disappearance of the starting material 
and appearance of a new species at Rt = 6.29 min. The crude product was then passed 
through a DSC-18 solid phase extraction cartridge with increasing amounts of 
acetonitrile in water (0.1% TFA). The coloured fractions were then further purified by 
semi-preparative HPLC. Freeze drying yielded AF350-CP6 as a light blue solid in 25% yield 
(Scheme 3.3.). 
The peptide with the dye attached has a maximum absorbance at 352 nm and a 
maximum emission at 443 nm corresponding to the anticipated values for the AlexaFluor 





















































































 Figure 3.6. Absorbance (blue) and fluorescence (red) spectroscopy of AF350-CP6, 10 
μM in PB (10 mM, pH 7). Excitation wavelength = 352 nm. 
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3.7 Fluorescence titration of AlexaFluor350 labelled peptide with hemin 
 
As the emission spectrum of the AlexaFluor350 label overlaps with the Soret absorption 
band of hemin it was anticipated that hemin binding to the peptide should result in 
effective fluorescence quenching. Therefore, adding hemin to a solution of AF350-CP6 
peptide should quench the fluorescence in proportion to how much hemin is present 
until all the binding sites of the peptide are occupied (at an equimolar concentration) 
and fluorescence quenching should plateau.  
However, upon addition of hemin to the peptide in solution, no quenching of the 
AlexaFluor 350 fluorescence was observed (Figure 3.7.). As resonance energy transfer is 
dependent on the distance between the donor and acceptor and the orientation of their 
dipole moments it is possible that conjugating the fluorophore at the N-terminus of the 
peptide places it too far away from the heme binding at the cysteine side chain, 5 amino 
acids away (Jares-Erijman and Jovin 2003). When attached to HO-1, the AlexaFluor350 
dye can be quenched by heme binding but the structure of HO-1 is more rigid than a 
small peptide and the dye is likely to be constrained at the correct distance from the 
binding site by the tertiary structure of the protein which is not achieved with the more 
flexible 9-mer peptide. Another possibility is that the fluorophore itself sterically blocks 
heme binding. This was tested by carrying out a UV-Vis titration with hemin but to 
overcome the brightness of the AlexaFluor 350 fluorophore, it was necessary to adjust 
the concentration of peptide and hemin to much lower than used previously. As such 












Figure 3.7. Fluoresence spectroscopy of AF350-CP6 with hemin. Peptide concentration was 
constant (10 μM) whilst hemin was titrated (0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2 μM, 3 μM, 4 
μM, 5 μM, 7.5 μM, 10 μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 25 μM) in phosphate buffer (10 
mM). After 2 min stirring the fluorescence was taken between 380 nm and 600 nm. The 
excitation wavelength was 350 nm, the slit widths for excitation and emission were 5 nm.   
 
3.8 Quenching of the intrinsic fluorescence of the tryptophan in CP3 by hemin 
 
In order to decrease the distance between the fluorophore and the bound hemin 
molecule, the fluorophore could be conjugated to an amino acid side chain following the 
Pro in the heme-binding peptide. This could be achieved by synthesis of the peptide with 
a lysine residue following the proline with a suitable protecting group that could be 
selectively removed to allow conjugation of the fluorophore only at that side chain. This 
would require a revision of the synthetic strategy in Scheme 3.1. 
However, the CP3 peptide has a tryptophan residue following its proline and tryptophan 
is fluorescent upon excitation at 280 nm, giving emission at 350 nm. Tryptophan 
fluorescence is often used as a readout to study protein conformation as its fluorescence 
is highly sensitive to its environment (Ghisaidoobe and Chung 2014). More recently, it 
has also gained popularity in the intrinsic Forster Resonance Energy Transfer (iFRET) 




















fluorophore. For example, it has been used to investigate ligand binding to proteins by 
monitoring energy transfer between a fluorophore labelled ligand and tryptophan 
residues found near the ligand binding site of the protein (Liao et al. 2009; Kim et al. 
2014).  
The absorption band of heme is quite broad and overlaps with the emission band of 
tryptophan (Figure 3.8.). Therefore, on addition of increasing amounts of hemin, and 










To assess this for CP3, the concentration of the peptide in phosphate buffer was kept 
constant (10 µM) while increasing the amount of hemin (from 0.25 µM to 25 µM). The 
peptide was excited at 280 nm and the emission spectrum recorded (Figure 3.9. A). As 
expected the emission peak of tryptophan (357 nm) is reduced on the addition of more 
hemin. By plotting the fluorescence of the peptide (F0) with the fluorescence at each 
hemin concentration (F) subtracted (F0-F), against the hemin concentration, the effect 
of hemin on fluorescence can be seen directly (Figure 3.9. B). F0-F increases steadily with 
Figure 3.8. Absorbance (blue) and fluorescence (green) spectroscopy of CP3 showing the 
overlap between CP3 fluorescence and hemin absorbance (red), 10 µM, PB pH 7.0. 
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increasing amounts of hemin until a 1:1 ratio of hemin:peptide is reached, after which 
F0-F plateaus as the binding sites are saturated. This data could also be used to generate 
a Kd by fitting the data to the same one site binding equation by replacing the absorbance 
with fluorescence. Fitting data is included in Appendix A.2. The average Kd (n=4) for 
hemin binding to the CP3 peptide was 0.44 ± 0.12 μM. This is four-fold lower than the Kd 
found by absorbance spectroscopy. Discrepancies between dissociation constants 
calculated using absorbance versus fluorescence spectra have been reported before and 
attributed to the use of different concentrations of binding partners between the two 
experiments; as fluorescence spectroscopy is more sensitive than absorbance, generally 
lower concentrations can be used (Koga et al. 2013; Thiabaud et al. 2013). However, in 
this work, the concentrations were equal across both platforms. Therefore, rather than 
the difference being caused by differing concentrations, it is likely that the difference is 
due simply to the difference in accuracies between the two techniques. Fluorescence 
spectroscopy is more sensitive than absorbance spectroscopy because fluorescence 
intensity is measured directly without comparison to a reference beam whereas 
absorbance spectroscopy measures the difference in light intensity between the beam 
passing through a buffer and passing through the sample (Sheehan 2009). Limits of 
optics and electronics make it difficult to detect small changes and small percentages of 
absorbed light making measurements at low concentrations difficult. Finding a Kd by 
absorbance spectroscopy also relied upon detecting a small shift in wavelength of the 
maximum absorbance of the Soret band on peptide binding, which changes throughout 
the experiment and the absorbance values at these shifting wavelengths whereas during 
the fluorescence quenching experiment the maximum wavelength is constant and 
simply the fluorescence value is measured.   
The modulation of tryptophan fluorescence on heme binding is promising for sensor 
development and proves that the position after the Cys-Pro motif is close enough for 
energy transfer to occur between the hemin and the tryptophan. However, tryptophan 
itself is not an ideal choice for a fluorophore for heme sensing in cells because of its 
natural occurrence in proteins. If a peptide such as CP3 was taken up by a cell it would 
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be very difficult, if not impossible to distinguish the fluorescence of the peptide probe 




Figure 3.9. Fluorescence spectroscopy of CP3 with hemin. Peptide concentration was 
constant (10 μM) whilst hemin was titrated (0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2 μM, 3 μM, 4 
μM, 5 μM, 7.5 μM, 10 μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 25 μM) in phosphate buffer (10 
mM). After 2 min stirring the fluorescence was measured between 300 nm and 550 nm. The 
excitation wavelength was 280 nm, the slit widths for excitation and emission were 5 nm.  A) 
Quenching of the fluorescence peak of CP3 with addition of hemin. B) F0-F (fluorescence of 
peptide – fluorescence at each hemin concentration) for CP3 with addition of hemin. Error 
bars show the standard deviation, n=4. 
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3.9 Incorporation of 7-azatryptophan into CP3 
 
Azatryptophans are analogues of natural tryptophan where one of the endocyclic CH 
groups of the indole is substituted with nitrogen. An azatryptophan is an attractive 
option for a replacement fluorophore for a number of reasons. Firstly, their fluorescence 
is red-shifted compared to normal tryptophan, allowing for their detection above the 
background tryptophan fluorescence of the cell (Merkel et al. 2010). Secondly, the 
substitution of carbon for nitrogen is the smallest possible structural alteration of 
tryptophan analogues and so their structure is very similar in size and shape to normal 








There is precedent for using 7-azatryptophan to monitor the binding between two 
species by taking advantage of its ability to be involved in Förster resonance energy 
transfer. 7-Azatryptophan for instance, has been incorporated into a 47 residue peptide 
based on the sequence of the thrombin inhibitor hirudin. A tyrosine at position 3 was 
replaced with 7-azatrytophan and the change in fluorescence on binding to thrombin 















Figure 3.10. Structures of tryptophan and 7-azatryptophan showing their peak excitation 
and emission wavelengths. 
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2004). 7-azatryptophan has also been incorporated into peptides based on the LysM 
motif of peptidoglycan binding proteins. Titrating ‘bacteria like particles’ onto the 
labelled peptide led to increased quenching of the azatryptophan fluorescence (Petrović 
et al. 2012). It was reported that the autofluoresence of the proteins used was more 
than 10-fold lower than the fluorescence of the 7-azatryptophan labelled peptides 
allowing them to be easily distinguished.     
 
7-Azatryptophan is commercially available as the L isomer in Fmoc protected form, 
meaning synthesis of a new peptide containing the residue is simpler and less time-
consuming than regioselectively modifying the peptide with a fluorophore would be, 
after its synthesis. CP3[7azaW] was synthesised on Rink Amide MBHA resin on a 0.6 
mmol scale and using Fmoc solid phase peptide synthesis (Scheme 3.4.). As previously, 
the first amino acid, Fmoc-Gly-OH was coupled manually using PyBOP as the activating 
agent and DIEA as the base and the rest of the peptide was completed on the Activotec 
automated peptide synthesiser using PyBOP activation. Cleavage from the resin and full 
side-chain deprotection was achieved using TFA/TIS/H2O/EDT (92.5:2.5:2.5,2.5, v/v/v/v). 
The peptide was purified by RP-HPLC to >98% purity as judged by analytical HPLC and its 
identity was confirmed by ESI-MS. Even though the indole ring of the azatyptophan was 
not protected (compared to Boc protection of the indole group used in Trp for CP3) no 
significant side products were observed and the desired peptide was successfully 
synthesised and purified. The incorporation of EDT in the deprotection cocktail helps 
prevent t-butylation of nucleophilic side chains by t-bu cations (Eberle et al. 1986) and 
use of Pmc as the protecting group for Arg rather than Mtr for example, also reduces the 
chance of potential sulfonation of Trp during cleavage from the resin (Riniker et al. 1990).  
Comparing the absorbance and fluorescence of the two peptides shows that substitution 
of tryptophan with 7-azatryptophan red shifts the absorbance of the peptide by 10 nm 
from 280 nm to 290 nm and the emission by 43 nm from 357 nm to 400 nm (Figure 
3.11.). These shifts are in agreement with those previously reported (Smirnov et al. 
84 
 
1997). Even the relatively small shift in the absorption peak of 7-azatryptophan should 
mean that the excitation wavelength used for detection can be shifted towards the red 
to the edge of the 7-azatryptophan absorption peak (310-320 nm) which is further red 
than for any absorption by tyrosine and the absorption by tryptophan is negligible. Even 
though red-shifted, the emission peak of 7-azatryptophan still largely overlaps with the 
absorption of hemin and so was expected to be quenched on hemin binding to the 
peptide. The red shift should therefore help in distinguishing the fluorescence of the 








Scheme 3.4. Synthesis of CP3[7azaW]. Reagents and conditions: a. Piperidine/DMF (1:4 v/v), 
5 + 10 min b. Fmoc-Gly-OH, DIEA, PyBOP, DMF, RT, 1 h; c. Piperidine/DMF (1:4 v/v), 5 + 10 
min; d. Fmoc SPPS: Fmoc-AA-OH, PyBOP, DIEA, DMF; e. TFA/TIS/H2O/EDT (92.5:2.5:2.5:2.5, 











3.10 Quenching of the fluorescence of 7-azatryptophan in CP3 by hemin 
 
To ensure that incorporation of 7-azatryptophan did not alter the heme binding ability 
of the peptide and that hemin binding can still be monitored by fluorescence quenching 
of 7-azatryptophan, a hemin titration was carried out as previously. Hemin (0.25 µM to 
25 µM) was added incrementally to a fixed concentration of CP3[7azaW] peptide (10 
μM) and the fluorescence spectra measured at each concentration.  
As with the original peptide, addition of hemin quenched the fluorescence maximum at 
402 nm. Plotting F0-F at the emission peak gave a very similar profile as for CP3 with 
fluorescence quenching plateauing after 10 μM hemin (1:1 equivalents of peptide and 
hemin). Using this data to calculate a Kd yielded 0.74 ± 0.42 µM which is comparable to 
the Kd found by fluorescence for unmodified CP3. Fitting data is included in Appendix 
A.2. 
Figure 3.11. Absorbance (blue) and fluorescence (green) spectroscopy of CP3[7azaW] showing 
the red shift compared to the fluorescence of CP3 (pink) and that there is still significant 















































Figure 3.12 Fluorescence spectroscopy of CP3[7azaW] with hemin. Peptide concentration 
was constant (10 μM) whilst hemin was titrated (0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2 μM, 3 
μM, 4 μM, 5 μM, 7.5 μM, 10 μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 25 μM) in phosphate 
buffer (10 mM). After 2 min stirring the fluorescence was measured between 300 nm and 
550 nm. The excitation wavelength was 290 nm, the slit widths for excitation and emission 
were 5 nm.  A) Quenching of the fluorescence peak of CP3[7azaW] with addition of hemin. 
B) F0-F (fluorescence of peptide – fluorescence at each hemin concentration) for CP3[7azaW] 






Peptides based on the CP motif heme binding sites of Bach1 have been successfully 
synthesised. Each has been shown to bind hemin in a cell-free system and the binding 
can be monitored by UV-Vis absorption spectroscopy. This allowed the calculation of a 
dissociation constant for heme binding for 3 of the Bach1 derived peptides. These Kds 
ranged from 33.9 ± 11.1 µM to 0.26 ± 0.24 µM, with CP6 having the strongest hemin 
binding capability. 
However, attempting to monitor heme binding intracellularly by UV-Vis absorption 
spectroscopy would be very challenging as it would be subject to a large amount of 
interference from various cellular components. Being able to follow heme binding by 
monitoring fluorescence is a much more attractive option as it is potentially both more 
specific and more sensitive.  
A blue fluorophore, AF350, that was previously used for a protein-based heme sensor 
was conjugated to the N-terminus of CP6 however, no modulation of fluorescence was 
observed on hemin binding. Focus was instead turned to fluorescent, non-natural amino 
acids. The CP3 sequence contains a natural tryptophan which exhibits fluorescence at 
357 nm when excited at 280 nm. On addition of hemin, this fluorescence is quenched as 
the hemin binds to CP3, bringing it into proximity with the tryptophan so that Förster 
resonance energy transfer can occur. The Kd found for hemin binding to CP3 in this way 
was 0.44 ± 0.12 μM. 
Tryptophan fluorescence is not very attractive for use intracellularly as it could be 
difficult to deconvolute from the background fluorescence of endogenous tryptophan 
found in cellular proteins. However, the azatryptophans are a readily available class of 
modified tryptophans with red shifted fluorescence compared to natural tryptophan. 7-
azatryptophan was incorporated into the sequence of CP3 and it was shown that the 
fluorescence of CP3[7azaW] at 402 nm was also quenched on binding to hemin in a 
manner that was proportional to hemin concentration until a 1:1 ratio of hemin:peptide 
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was reached. The Kd found for this interaction was 0.74 ± 0.42 µM which is comparable 
to the Kd for unmodified CP3 peptide, showing that the substitution of Trp for 7-
azatryptophan does not hinder hemin binding. 
This newly synthesised peptide therefore has potential for use as a heme sensor but 















4 Synthesis of peptide probes based on the amino acid sequence 





Hemopexin is a plasma glycoprotein that binds heme. It has a molecular weight of 60 
kDa and consists of a single polypeptide chain of 439 amino acids. It has the strongest 
affinity for heme of any known protein with a Kd of 10-13 M reported for the native 
protein isolated from human blood (Hrkal et al. 1974), although a higher Kd  of 10-8 M 
has been reported for a recombinant protein (Satoh et al. 1994). Heme-bound 
hemopexin is recognised by the receptor LDL-receptor-related protein-1 (Hvidberg et al. 
2005) and binding leads to internalisation. The receptor is expressed by several cell types 
including hepatocytes, macrophages and neurons indicating the use of heme in multiple 
cell types. As hemopexin has such a high affinity for heme, it ensures that any free heme 
is quickly bound and neutralised, thereby preventing damage that could be caused by 
free heme and delivering it back to the liver for recycling and thus conserving energy. 
The aim of this chapter was to design peptides based on the heme-binding sequence of 
hemopexin with stronger affinities for heme than the peptides discussed in Chapter 3. 
 
4.1.1 The heme binding site of hemopexin  
 
Hemopexin consists of two domains, each with the same β-propeller fold, consisting of 
four β-sheets. The heme binding site is at the interface between these two domains and 
each domain provides one face of the heme binding site (Paoli et al. 1999) (Figure 4.1.). 
There is a flexible linker between the two domains that could not be resolved in the 
crystal structure and is also the least conserved sequence region. The linker could be in 
a position to close the heme binding pocket but if it does interact with heme, it is likely 
not an important interaction. The heme propionates are buried in the pocket of the 
protein, whereas the more hydrophobic side of the heme faces out of the pocket. The 
central heme iron is coordinated by two histidine residues, one from the start of the loop 
bridging the two domains (H213) and the other from the C-terminal domain (H266). 
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Apart from these axial ligands, the binding pocket has an abundance of aromatic and 
positively charged residues which are highly conserved between species. There are 
seven aromatic residues, 6 of which are from the N-terminal domain (W171, Y176, Y197, 
F183, Y204, F205) with only W267 from the C-terminal side. It is likely that there is edge 
to face π-stacking between Y204 and W267 with the face of the heme, as well as side 
chain stacking between the pairs of Y204 and H213 and W267 and H266 that help 
stabilise the binding site. There are four basic residues: R174, R185 from the N terminal 
domain and H271 and H222 from the C terminal domain. Along with Y267 these residues 
surround the propionates of the heme and provide hydrogen bonding partners. 
 
 
Figure 4.1. The binding site of rabbit hemopexin (1QH). The N-terminal domain is in blue and the 
C-terminal domain is in green. The heme porphyrin is shown in orange with the two coordinating 
histidines (H213 and H265) in black. The aromatic residues (W171, Y176, Y197, F183, Y204, F205 
and W267) are in red and the basic residues (R174, R185, H271 and H222) are purple. The figure 




4.2 Sequence alignment of hemopexin amino acid sequences 
 
Analysis of the crystal structure of rabbit hemopexin (Figure 4.1.) has revealed the shape 
of the heme binding site and the residues that interact with heme. However, to gain a 
further understanding of the important residues for heme binding a sequence alignment 
was undertaken using the protein sequence from a number of different species (Figure 
4.2.). Residues that are critical or important for protein function are usually highly 
conserved across species because any deviation from the best sequence can lead to loss 
of function and is evolutionarily selected against. Therefore, highly conserved residues 
would be important to consider including in any heme binding peptide to be synthesised 
based on the heme binding site of hemopexin. 
Eight hemopexin sequences were taken from UniProtKB and aligned by Clustal Omega 
(Figure 4.2.).  
 
The sequence of the hemopexin heme binding site is well conserved across mammals. It 
is less conserved in zebra fish, but most of the aromatic and positive amino acids 
identified as important for binding in the crystal structure of rabbit hemopexin (Figure 
4.1.) are still conserved or substituted for other aromatic or positive residues (e.g. Tyr 
for Trp). The peptide chain that links the two domains is the least conserved region of 








sp|Q91X72|HEMO_MOUSE      RSWSTVGNCTAALRWLERYYCFQGNKFLRFNPVTGEVPPRYPLDARDYFVSCPGRGHGRPRNGTAHGN 246  
sp|P20059|HEMO_RAT        RSWPAVGNCTAALRWLERYYCFQGNKFLRFNPVTGEVPPRYPLDARDYFISCPGRGHGKLRNGTAHGN 246 
sp|Q3SZV7|HEMO_BOVIN      RSWPAVGNCSSAIRWLNRYYCFRGNKFLRFDPVTGEVNSTYPRDVRDYFMSCPNRGHAH-RNATQHM- 246 
sp|P50828|HEMO_PIG        RLWPAVGNCSSAMRWISRYYCFRGNQFLRFDPVTGHVDPKYPRDVRDYFMSCPGRGHAH-RNATHRG- 246 
sp|P20058|HEMO_RABIT      RSWPAVGNCTSALRWLGRYYCFQGNQFLRFNPVSGEVPPGYPLDVRDYFLSCPGRGHRS-----SHRN 244 
sp|P02790|HEMO_HUMAN      RSWPAVGNCSSALRWLGRYYCFQGNQFLRFDPVRGEVPPRYPRDVRDYFMPCPGRGHGH-RNGTGHGN 248 
sp|Q5R543|HEMO_PONAB      RSWPAVGNCSSALRWLGRYYCFQGNQFLRFDPVRGEVPPRYPRDVRDYFMPCPGRGHGH-RNGTGHGN 246 
                          : : :: **:.*:*:: :****:*.:* :*:*: *.*   ** :.****: **  *    
          
sp|Q91X72|HEMO_MOUSE      STH--PMHSRCSPDPGLTALLSDHRGATYAFTGSHYWRLDSSRDGWHSWPIAHHWPQGPSTVDAAFSW 312 
sp|P20059|HEMO_RAT        STH--PMHSRCNADPGLSALLSDHRGATYAFSGSHYWRLDSSRDGWHSWPIAHHWPQGPSAVDAAFSW 312 
sp|Q3SZV7|HEMO_BOVIN      -------DKRCSPHLVLSALLSDNHSATYAFSENHYWRLDSSRDGWHSWRIEHLWPQGPSTVDAAFLW 312 
sp|P50828|HEMO_PIG        -------DDRCSPDLVLTALLSDNHGATYAFRGTHYWRLDTSRDGWHSWPIDHQWSHGPSAVDAAFSW 312 
sp|P20058|HEMO_RABIT      STQHGHESTRCDPDLVLSAMVSDNHGATYVFSGSHYWRLDTNRDGWHSWPIAHQWPQGPSTVDAAFSW 312 
sp|P02790|HEMO_HUMAN      STHHGPEYMRCSPHLVLSALTSDNHGATYAFSGTHYWRLDTSRDGWHSWPIAHQWPQGPSAVDAAFSW 314 
sp|Q5R543|HEMO_PONAB      GTHHGPEYMRCSPHLVLSALTSDNHGATYAFSGTHYWRLDTSRDGWHSWPIAHQWPQGPSTVDAAFSW 314 
               :*     * *: **. .  *.*   *:  :  . * :**  *   : .  * **:.* : 
 
 
Figure 4.2. An excerpt from the multiple sequence alignment of hemopexin, showing the two histidine residues that coordinate the iron 
atom of heme (highlighted yellow). The aromatic and basic residues identified in Figure 4.1 as being important for heme binding are also 
shown (highlighted blue). Sequence alignment was performed by Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Species 
included are mouse, rat, cow, pig, rabbit, human and orangutan. 
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4.3 Design and synthesis of a peptide based on hemopexin 
 
In order to design a potential heme-binding peptide, the information gained from both 
the crystal structure of rabbit hemopexin and the sequence alignment was taken into 
account. Two histidine residues were included to coordinate one iron of heme, with the 
peptide forming a ‘claw shape’ around the planar heme molecule. With two coordinating 
residues it was hoped that hemin binding would be very effective. Aromatic residues 
were included to provide an opportunity for π-π stacking between the side chains and 
the porphyrin ring. Polar residues were also included to provide interactions with the 
propionate side chains of heme. As other positively charged residues could conceivably 
compete with the histidine residues for iron binding, positively charged residues from 
the crystal structure were substituted for other polar amino acids that would not run 
this risk but could still act as hydrogen bonding partners for the heme propionates.  
A glycine was added at the N-terminus of the designed peptide to mimic the 
continuation of the native protein chain, followed by a histidine residue to coordinate 
the iron, mimicking H265. The peptide then follows the protein chain and takes the same 
residues through Ser266, Trp267, Pro268, Ile269, Ala270 and instead of His271, a Glu is 
substituted. A Gly was added to bridge the gap between the C-terminal and N-terminal 
domains. A Ser was added to the peptide sequence to reproduce the interactions 
observed between heme and Arg174 in the protein structure. An Ala was then included 
as a bridge to a threonine residue which was added as a substitute to provide 
interactions with heme as the Arg185 does in the native protein. The residues from the 
protein’s β-strand were then followed; a Leu, a Phe and then a Tyr to imitate the 
protein’s Tyr205. A Gly was added as a bridge to the second His included for binding to 
be analogous to His213. Finally, as at the N-terminus, a Gly was added at the C-terminus 
of the designed peptide to simulate the continuation of the hemopexin protein chain. 
The final design of the hemopexin based peptide, HXNP1, is summarised in Figure 4.3.  
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The peptide was synthesised as described in Chapter 3 by Fmoc solid phase peptide 
synthesis. It was purified by semi-preparative HPLC. Freeze drying yielded of HXNP1 as 





Scheme 4.1. Synthesis of HXNP1. Reagents and conditions: a. Piperidine/DMF (1:4 v/v), 5 + 10 
min b. Fmoc-Gly-OH, DIEA, PyBOP, DMF, RT, 1 h; c. Piperidine/DMF (1:4 v/v), 5 + 10 min; d. Fmoc-
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the porphyrin ring 
Histidine residues to interact 
with the iron of hemin 
A 
Figure 4.3. A) Schematic explaining the design of a potential heme-binding peptide, HXNP1 
based on the hemopexin binding site. B) Structure of hemopexin binding site with residues that 
were chosen for the peptide in blue and green. The figure was created using The PyMOL 
Molecular Graphics System, Schrödinger, LLC. 
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4.4 NMR of HXNP1 
 
1H NMR was employed to gain some preliminary insights into the solution structure. 
The 1H COSY spectrum (Appendix A.3.) was used to assign areas of the spectrum to 
specific residues found in a peptide and the 1H NMR spectrum with regions assigned is 
shown overleaf (Figure 4.4).  All the resonances in the spectrum appear well dispersed 
and sharp and some of the NH resonances are downshifted above 8.5 ppm which all 
suggest that the peptide is in a stable conformation in solution. Broader linewidths can 
indicate that the peptide can fluctuate between different conformations but the line 
shape is quite defined and the peaks are sharp suggesting that the peptide is folded in 
an low energy optimised conformation. 
Spectra were also obtained for a 1:1 mixture of the peptide and hemin in an attempt to 
reveal some specific details of the binding interaction. The spectrum was changed 
significantly compared to the spectrum of the peptide alone, with slightly broader line 
shapes and up-field shifting of multiple resonances. However, it was impossible to 
conclude if these changes were due to binding or simply due to the presence of the 
paramagnetic Fe3+ ion of hemin as illustrated previously (Thiabaud et al. 2013). 







Figure 4.4. 1H NMR spectrum of a DMSO-d6 solution of the designed heme-binding peptide 
HXNP1 with chemical shift regions assigned to peptide features. 
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4.5 Heme binding to HXNP1 
 
The newly designed and created peptide (HXNP1) was tested for its hemin binding 
ability, as for the shorter peptides in Chapter 3. The Soret band of hemin shifted from 
387 nm to 395 nm upon peptide binding. The difference spectrum shows a broad, deep 
minimum at 377 nm and a maximum at 418 nm (Figure 4.5). Compared to the CP 
peptides discussed in the previous chapter, it was anticipated that the binding of HXNP1 
should be stronger (and therefore the Kd lower) due to the potential for more 
interactions with hemin built into this longer peptide. In this context, a 23 residue 
peptide with a Cys-Pro motif investigated by Kühl et al. had a Kd of 1.42 ± 0.24 µM for 
hemin binding. Although this was not significantly lower than the other 9-mer peptides 
tested, given the additional design elements based on the binding site of hemopexin, a 
much smaller Kd was expected for HXNP1. 
 
The difference absorbance plot obtained for HXNP1 and hemin indicates that hemin was 
binding to the peptide. The plot shows a minimum at 377 nm and a maximum at 418 
nm. This pattern is remarkably similar as the Group 1 peptides defined by Kühl et al. 
(2013) which suggests that selective iron mediated binding to the peptide is occurring. 
It is also very similar to the reported difference absorbance plot of heme binding to 
hemopexin protein, which also had a minimum followed by a maximum at 418 nm in PB 
at pH 7.0 (Hrkal et al. 1974).  However, the plot of hemin concentration against 
ΔAbsorbance does not reach a plateau, suggestion saturation of the peptide with hemin 






HXNP1 was designed to bind hemin in a 1:1 ratio, however various other types of 
interaction could be imagined. If the interaction was between two molecules of hemin 
and one peptide, then the peptide would have become saturated quicker and the 
difference absorbance should have plateaued at a hemin concentration of 10 µM (0.5 
equivalents of hemin to peptide). If two molecules of peptide were coordinating one 
A B 
C D 
Figure 4.5. UV-Vis titration of hemin binding to HXNP1. A) Full spectra of HXNP1 with increasing 
hemin concentration. B) Difference spectra of the HXNP1-hemin complex. C) The difference 
absorbance in relation to hemin concentration at the 418 nm peak. D)  The difference 
absorbance in relation to hemin concentration at the 377 nm minimum. Peptide concentration 
was constant (20 μM) whilst hemin was titrated (0.4 μM, 0.8 μM, 1.2 μM, 1.6 μM, 2 μM, 4 μM, 
6 μM, 8 μM, 10 μM, 15 μM, 20 μM, 25 μM, 30 μM, 35 μM, 40 μM) in phosphate buffer (10 mM). 
After 15 min stirring the absorbance was measured between 200 nm and 800 nm. 
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molecule of hemin, then the difference absorbance would start to plateau after 40 µM 
which was not exceeded in this experiment. The structure of HXNP1 also makes it seem 
unlikely that two peptides are coordinating one hemin while the other histidine residues 
are left free. However, what could be happening is that the peptide is forming higher 
order complexes, with longer chains forming between one hemin and the histidines of 








Supporting the idea of higher order complex formation, the difference absorbance data 
for HXNP1 binding to hemin did not fit to the one-site binding equation that the data for 
the CP peptides of Chapter 3 were fitted to. It also did not fit to the 2:1 or 1:2 binding 
equations which further suggests that larger complexes may be formed (Thordarson 
2010). 
 
4.6 Investigating the binding stoichiometry of heme to HXNP1 
 
In order to further explore the stoichiometry of hemin binding to HXNP1 a Job plot was 
constructed as previously. 
 
Figure 4.6. A scheme showing the proposed architecture of the possible higher order 
complexes forming between hemin and HXNP1. The peptide chain is represented in blue 














The Job plot (Figure 4.7) shows that the two lines intersect at a hemin mole fraction of 
0.56 which equates to a binding stoichiometry of 1.3 hemin molecules to one peptide.  
 
There are some limitations to using the Job plot to assign stoichiometry in a system that 
does not follow 1 to 1 binding (Thordarson 2010). When the binding is not simply 1 to 1 
then there is more than one species in the solution. For example, for 2 molecules of 
hemin binding to one peptide, then there would be both the 1 to 1 and 2 to 1 complexes 
in equilibrium in the solution. These different complexes would be expected to have 
different physical properties and therefore it cannot be completely assumed that the 
property of interest (in this case absorbance) is still linearly dependent on the fraction 
























Figure 4.7. Job plot of hemin with HXNP1. Total molar concentration of peptide and hemin (10 
µM) was constant while the mole fraction of each component was varied in PB (10 mM, pH 7). 
104 
 
of the highest order complex, as the lower order complex will have its own absorbance 
profile that could be interfering.   
 
4.7 Circular dichroism spectroscopy 
 
The peptide was designed to form a claw conformation around the heme molecule, 
however, the indication that larger order complexes are present suggests that the 
peptide is not sufficiently constrained to the claw shape and is flexible enough to allow 
different heme molecules to bind to each histidine. To investigate this further, the 
conformation of HXNP1 in solution was investigated by circular dichroism spectroscopy 
(CD). Circular dichroism is a spectroscopic method that can give insight into the 
secondary structure of proteins and peptides (Kelly et al. 2005). 
Plane polarised light can be thought of as consisting of two components, that are each 
circularly polarised and of equal magnitude but rotating in opposite directions, one left 
handed and one right handed. Circular dichroism is the unequal absorption of these two 
oppositely rotating components of circularly polarised light. When asymmetric 
molecules are placed in this light they will absorb the polarised light unequally and the 
recombination of the light that passes through a sample will possess elliptical 
polarisation. 
In proteins, the chromophores that absorb polarised light include the peptide bond, 
aromatic side chains and disulfide bonds. If a number of chromophores of the same type 
are in close proximity, they can behave as a single absorbing unit which will give rise to 





Figure 4.8. Typical CD spectra profiles of elements of protein structure. Adapted from Brahms 
and Brahms, (1980).  
 
Absorption below 240 nm is mostly due to the peptide bond and the presence of regular 
secondary structure gives rise to characteristic spectra in the far UV region (Figure 4.8.). 
α-Helices have a double minimum at 222 nm and 208 nm and a positive band at 193 nm. 
β–Sheets give a negative maximum at 218 nm and a positive maximum at 195 nm. Very 
disordered peptide chains have very negative ellipticity around 200 nm which rises to 
near 0 around 220 nm.  Due to these characteristic patterns, CD can be used to estimate 
the structure of unknown proteins and also to monitor any changes in conformation due 
to different conditions or ligand binding (Greenfield 2007). 
 
A peak at 205 nm is characteristic of a type II β-turn which is what was expected with 
HXNP1 if the peptide adopted a bend to form a claw around the hemin. However, in 
phosphate buffer, CD of HXNP1 shows that it apparently has a very unordered 
conformation (Figure 4.9). This is not entirely unexpected as a peptide of this length 
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would not be expected to show a much defined α-helical or β–sheet structure. Addition 
of hemin also did not change the structure of the peptide however, suggesting that a 
turn structure in the peptide is not induced by hemin and that it is indeed unlikely that 
one peptide is binding one hemin through two histidine residues, which may help explain 
why it was not possible to fit the ΔAbsorbance data from the UV-Vis hemin titration to 
any of the binding equations. Phosphate buffer is a physiologically relevant medium but 
methanol, as a less polar solvent can also give some insight into peptide structure when 
less hydrogen bonds are possible with the solvent, thereby making it more favourable 
for the peptide to form more intramolecular interactions (Cox et al. 1993). In methanol, 
HXNP1 gave a spectrum much more characteristic of α-helical configuration and again, 

































Figure 4.9. Circular dichroism spectroscopy of HXNP1 (5 µM, 10 mM PB, pH 7.0) (blue) with 1 
equivalent (green) of hemin. A in phosphate buffer. B in methanol. 
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4.8 Design and synthesis of HXNP2 
 
If HXNP1 is able to adopt a rather flexible conformation in solution, this could be the 
reason for its failure to bind hemin in the designed one to one ratio. To address this the 
sequence of HXNP1 was adapted to include a specific β-turn motif to induce the peptide 
chain to adopt a folded conformation in solution around one molecule of hemin. A β-
turn is a non-repeating secondary structure that causes a reversal in the peptide chain.  
Each β-turn consists of 4 amino acids designated i, i+1, i+2 and i+3 and the turn is 
stabilised by a hydrogen bond in the peptide backbone between the CO of residue i and 
the NH of residue i+3 (Figure 4.10). The ideal dihedral angles for amino acids in the 












Figure 4.10. Two types of β-turns with the tetrapeptide Cα atoms denoted as 1, 2, 3, 4. Turn type I 
has (φ, Ψ)2 of (-60°, -30°) and (φ, Ψ)3 of (-90°, 0°). Turn type II has (φ, Ψ)2 of (-60°, -120°) and (φ, Ψ)3 
of (90°, 0°). Adapted from (Chou and Fasman 1977) 
 
- 
II has (4, I,/J)~=(-60”, 
120”) and (4, #)3=800, 0”). 
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Turn type i+1 φ° i+1 Ψ° i+2 φ° i+2 Ψ° 
I -60 -30 -90 0 
I’ 60 30 90 0 
II -60 120 80 0 
II’ 60 -120 -80 0 
Via -60 120 -90 0 
VIb -120 120 -60 0 
VIII -60 -30 -120 120 
Table 4.1. The ideal dihedral angles (Ψ, Φ) of amino acids in the i+1 and i+2 positions of different 
classes of β-turns. 
 
Proline has a Ψ angle of -65° due to its cyclic side chain making it a good candidate for 
the i+1 position of a Type II β-turn. Glycine, on the other hand, is a small amino acid with 
only a hydrogen atom as a side chain. This means its dihedral angles can cover a wide 
range of values. Proline and glycine are therefore commonly found at the i+1 and i+2 
positions of Type 2 β-turns (Wilmot and Thornton 1988) and glycine especially is highly 
favoured over any other residue at i+2. As there is a glycine residue already at the centre 
of HXNP1, this was identified as a potential site for nucleating a β-turn. Gln is also the 
second most likely amino acid to be found at the i position in Type II β-turns (Chou and 
Fasman 1977) so this residue of HXNP1 could be retained. Ser is not particularly favoured 
at the i+4 position but it is not strongly selected against either and so it was decided to 
keep it in the modified peptide sequence based on the hemopexin binding site. It was 
therefore concluded that the simplest alteration to the HXNP1 sequence to induce a β-
turn was to insert a Pro residue between the central Gln and Gly residues (Figure 4.11.). 
In order to promote the formation of a β-turn in the desired location without the chain 
kinking at any other place, the Pro that occurred earlier in the sequence was substituted 
















The new peptide, HXNP2, was synthesised as above by Fmoc solid phase peptide 
synthesis and purified by semi-preparative HPLC. Freeze drying yielded HXNP2 as a white 
solid, in 14% yield (Scheme 4.2.). 
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Figure 4.11. Schematic explaining the design of a second peptide, HXNP2, based on the hemopexin 




Scheme 4.2. Synthesis of HXNP2. Reagents and conditions: a. Piperidine/DMF (1:4 v/v), 5 + 10 
min b. Fmoc-Gly-OH, DIEA, PyBOP, DMF, RT, 1 h; c. Piperidine/DMF (1:4 v/v), 5 + 10 min; d. Fmoc-




4.9 CD of HXNP2 
 
Now that the peptide sequence contained amino acids with a higher propensity to form 
β-turns, CD spectroscopy was used again to investigate whether the peptide had indeed 
been constrained into forming the desired folded structure, based around a type II β-
turn (Figure 4.12).  
In phosphate buffer the spectrum of HXNP2 remained very similar to the spectrum of 
HXNP1 which is again characteristic of an unordered peptide chain in solution. In 
methanol the predominant structure stills seems to be α-helical and so it seems that 
introducing the proline residue into the HXNP1 sequence did not result in the desired 

































Figure 4.12. Circular dichroism spectroscopy of HXNP2 (5 µM, 10 mM PB, pH 7.0) (blue) with 1 
equivalent (green) and 2 equivalents (red) of hemin. A in phosphate buffer. B in methanol. 
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4.10 Binding stoichiometry of hemin to HXNP2 
 
Even though no β-turn structure could be observed with CD spectroscopy for HXNP2, a 
Job plot was constructed with hemin and HXNP2 to see whether any clear heme-binding 












The Job plot (Figure 4.13) shows that the two lines intersect at a hemin mole fraction of 
0.62 which equates to a binding stoichiometry of 1.6 hemin molecules to one peptide. 
Again this ratio cannot be easily rationalised when looking at the structure of the peptide 
and is not consistent with a single binding stoichiometry between the peptide and 
hemin. Once more, the results suggest that a number of different peptide/hemin 
complexes are formed in solution. 
Figure 4.13. Job plot of hemin with HXNP2. Total molar concentration of peptide and hemin (10 
µM) was constant while the mole fraction of each component was varied in PB (10 mM, pH 7). 




























This chapter set out to create a peptide with a much lower dissociation constant than 
the CP peptides discussed in the previous chapter. In order to achieve this, a peptide was 
designed based on the heme binding site of hemopexin, the protein with the highest 
known affinity for heme. The peptide included two histidine residues that were designed 
to both provide coordination for one molecule of heme. However, including two 
histidine residues appeared to complicate the binding of hemin to the designed HXNP1 
peptide. Although hemin does bind to HXNP1, as shown by the minimum and maximum 
features of the difference absorbance, the Job plot and the failure to fit the titration data 
to a 1:1 binding equation demonstrate that HXNP1 does not bind hemin in an equimolar 
ratio thus making it unsuitable for further development. CD spectroscopy showed that 
HXNP1 was very flexible in solution and so a new peptide, HXNP2, was designed to try 
to constrain the peptide into a locked conformation so that sterically, only one potential 
heme binding site was created. However, CD spectroscopy of this peptide also showed 
an unordered confirmation in solution and the Job plot again did not show a 1:1 binding 
stoichiometry.  Development of this peptide was therefore halted. 
 
One possible way to further investigate the binding of hemin to the HXNP peptides 
would be to employ Raman spectroscopy to ascertain whether the iron at the centre of 
the hemin molecule is penta- or hexacoordinated (Kühl et al. 2013). Pentacoordination 
would indicate only one histidine binding to each hemin molecule whereas 
hexacoordination would prove that each hemin was bound by two extra ligands.  
 
Whatever the true dynamics of the binding between hemin and HXNP1 or HXNP2, 
further development is needed to design a peptide derived from hemopexin that can 
bind hemin in the desired 1:1 ratio with a low Kd. Perhaps the simplest thing to try as a 
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first step would be to resynthesize the peptide but with only one histidine (and therefore 
one potential heme binding site) and then find its dissociation constant with a hemin 
titration. If the Kd with only one iron coordinating side chain residue is still high, and it is 
deemed that two are necessary, then further modification of the peptide could be 
trialled to further induce a β-turn. For example, in the i+3 position Arg and Gln are highly 
favoured. In peptide design other positive amino acids were avoided to prevent further 
heme binding sites so including an arginine to induce a β-turn would be 
counterproductive. However, a Gln could be added to the sequence.  
 
Given the difficulties in monitoring heme binding to the hemopexin based peptides, the 
shorter CP peptides from the previous chapter were returned to for further 
















Given the difficulties encountered in the previous chapter in determining the 
stoichiometry and dissociation constant for the longer peptides based on the hemopexin 
sequence, it was decided to return to the peptides from Chapter 3.  It had been 
established there that short Cys-Pro containing peptides derived from the Bach1 
sequence could bind hemin effectively and CP3[7azaW] was established as a lead 
peptide. This chapter is therefore concerned with the further development of this 
peptide and establishing whether it could be used as a heme sensor in biological 
samples.  
 
There are certain criteria that a peptide sensor should fulfil if it is to be used 
intracellularly. It should be able to enter cells easily and quickly and when internalised, 
be non-toxic to cells and not affect their usual processes.  It must also be possible to 
monitor the sensor in cells by fluorescence spectroscopy and microscopy and therefore 
a fluorophore is needed that will be compatible with commonly used detection methods 
and instrumentation of these types.   
 
Incorporating a cell penetrating peptide (CPP) sequence would be one way that should 
ensure cell permeability of the sensor. CPPs are short peptide sequences, usually 
between 8-30 amino acids long, and many well-known CPPs have a high proportion of 
basic residues, like the Tat(48-60) (GRKKRRQRRRPPQ) and polyarginine sequences (Rn (n = 
6-12)). Other well-known CPPs are amphipathic like Pep-1 
(KETWWETWWTEWSQPKKKRKV) (Zorko and Langel 2005). CPPs are capable of 
manipulating the cellular machinery to trigger endocytosis, or can cross the cell 
membrane directly (Mueller et al. 2008). When various other molecules (ranging from 
small molecule drugs to proteins) are combined either covalently or non-covalently, with 
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CPPs, they are efficiently transported across the membrane where alone only poor 
internalisation would be achieved (Copolovici et al. 2014).  CPPs therefore have potential 
for use for a number of biological applications such as delivery of therapeutics, imaging 
and sensing (Fonseca et al. 2009; Stewart et al. 2008). A recent example that is 
particularly relevant to this work is the use of an octa-arginine CPP to help deliver a 
peptide helix tagged with the fluorescent probe 4- nitrobenzo-2-oxa-1,3-diazole, that 
could then be attached to different proteins for imaging (Nomura et al. 2015).  
 
5.2 Detection of heme in cell extracts with CP3[7azaW] 
 
Initially, the ability of CP3[7azaW] to bind and detect heme in cell lysates was 
investigated.  FEK4 cells were either treated with 10 µM hemin for 18 h, or 250 kJ/m2 
UVA irradiation before collection and lysis by sonication in lysis buffer with protease 
inhibitors. The total protein content of the lysates was assessed by the BCA assay so that 
the concentration of cellular extract could be standardised for treatment with a heme 
sensor peptide (Noble and Bailey 2009). The BCA assay is a colourimetric assay in which 
protein reduces Cu2+ to Cu+ which then reacts with bicinchoninic acid to produce a 
purple solution.  Differing amounts of cell lysates were then mixed with 10 µM 
CP3[7azaW] in UV transparent 96 well plates (UV-Star®, Greiner Bio-One), and the 
fluorescence was measured by exciting at 320 nm in a CLARIOstar fluorescence plate 

















Figure 5.1. Detecting heme in cell lysates with CP3[7azaW]. Cells were either untreated (blue), 
treated with 10 µM hemin for 18 h (red) or 250 kJ/m2 UVA irradiation (green) and then lysed by 
sonication. CP3[7azaW] (10 µM) was then incubated with differing amounts of cell lysate 
(determined by protein concentration). Fluorescence of peptide alone was designated F0. n=1 (2 
µg, 10 µg, 20 µg, 30 µg), n=4, mean with SEM (5 µg). 
 
The fluorescence of peptide alone was designated as F0, so that an increase in F0-F 
represents fluorescence quenching which can be assumed to be due to heme binding to 
the peptide (Figure 5.1.). Initially the peptide was tested with a range of different lysate 
amounts, determined by the total protein content of the lysate. A similar trend was seen 
with all lysate amounts and it was decided that 5 µg of cell lysate was enough to cause 
determinable changes in the fluorescence of CP3[7azaW] and so repeats were 
subsequently performed only with 5 µg of cell lysate. 
F0-F was found to increase compared to peptide alone in all cell lysates, with a greater 
increase seen with higher amounts of lysate used. In all cases, as expected, more 
quenching was seen when the cells were loaded with hemin compared to the untreated 
cells suggesting that the peptide was indeed detecting changes in heme levels. F0-F was 












further increased by treatment with UVA irradiation compared to untreated cells (p = 
0.06) suggesting that UVA irradiation directly increases free heme.  
 The process did not involve any treatment that should disrupt protein structure, and 
protease inhibitors were included to help protect cellular proteins from degradation by 
cellular proteases. The heme detected by this fluorescence quenching should therefore 
represent cellular free heme only and not any heme bound to hemoproteins within the 
cell lysate.  
 
5.3 Toxicity of peptide to cells 
 
As the ultimate aim is to use a heme-sensing peptide in cells, it is essential that such 
molecules be non-toxic and not affect the metabolism or heme levels of the cell under 
study.  The toxicity of the test peptide was evaluated using the MTT assay (Meerloo et 
al. 2011). FEK4 cells were seeded and left to adhere before being treated with the 
peptide for 48 h. The cells were then washed and treated with the MTT dye which is 
reduced by the cellular enzymatic machinery to an insoluble formazan. Any remaining 
dye was then removed by washing and the cells were treated with DMSO to dissolve the 
formazan into a coloured solution. The absorbance of this solution represents the 
activity of NAD(P)H-dependent cellular oxidoreductase enzymes which are an indication 
of the viability of the cells present. If the peptide diminishes the growth of the cells, then 
less formazan will be produced compared to the untreated cells and the absorbance will 


















Figure 5.2. MTT assay to assess toxicity of CP3[7azaW] in FEK4 cells. Cells were seeded in a 96 
well plate for 24 h before being treated with peptide (0 M, 0.1 µM, 10 µM, 50 µM, 100 µM, 1 
mM, 5 mM, 10 mM, 25 mM) in duplicate for 48 h before addition of MTT reagent for 3 hours. 
Absorbance was standardised to the untreated cells which was set at 100% viability. Error bars 
show standard deviation, n=3. 
 
Figure 5.2. shows the result of the MTT assay to assess the toxicity of CP3[7azaW] in 
FEK4 cells. There was no difference observed between the cells treated with peptide 
and the untreated cells. At the highest concentrations there was a slight decrease in 
cellular enzyme activity but these concentrations (5 mM – 25 mM) are 10× higher than 
would typically be used in a cellular assay. The cells were also exposed to the peptide 
for 48 h which is much longer than would be required for a heme sensing assay. 
Therefore, it can be concluded that the lead peptide is likely to be non-toxic to cells 




5.4 Conjugation of 5-carboxy-X-rhodamine to the N-terminus of CP3[7azaW] 
 
As already noted, in order to measure heme levels intracellularly it must be possible to 
quantify the amount of peptide sensor that is taken into the cell. Using the fluorescence 
of 7-azatryptophan to do this would be inappropriate because any heme binding would 
quench its fluorescence and therefore it would appear there was less peptide in the cell 
than there actually was. Coupling a second, independent fluorophore to the peptide 
would be a solution to this. As the excitation wavelength of 7-azatryptophan is in the 
near UV region, it would be impractical to select a second fluorophore with a shorter 
wavelength. Therefore, a fluorophore with an excitation wavelength longer than the 
emission wavelengths of heme was required. This should allow it to be excited 
independently at a longer wavelength that would not interfere with the signal from 
either 7-azatryptophan or heme. A second fluorophore would also allow the cell to be 
more easily detected by fluorescence microscopy. The 7-azatryptophan fluorophore 
requires excitation in the middle UV region, and most fluorescence microscopes are not 
equipped to excite at such a short wavelength, with most only having a 405 nm diode 
for DAPI fluorescence as the lowest wavelength source.  
 
5-Carboxy-X-rhodamine (5-ROX) was identified as having desirable spectroscopic 
properties, with an absorption maximum at 578 nm and emission maxima at 593 nm. A 
succinymidyl ester of 5-carboxy-X-rhodamine (5-ROX-SE) was chosen as a simple means 
to conjugate this dye with the N-terminus of the lead CP3 peptide. As this peptide has a 
Lys residue at the N-terminus with a free amino group in its side chain, this provides an 
alternative conjugation site for 5-ROX that would potentially compete with the amino 
group at the N-terminus. To avoid this problem, the CP3[7azaW] peptide was therefore 
resynthesized with this Lys substituted for a neutral Ala – ACP3[7azaW] - before the 




ACP3[7azaW] (2 eq) was incubated with 5ROX-SE in NaHCO3 pH 8.3, at room 
temperature, protected from light (Scheme 5.1.). The reaction was monitored by HPLC 
which showed disappearance of the starting material and appearance of a new species 
at Rt =6.26 min. The crude product was then passed through a DSC-18 solid phase 
extraction cartridge with increasing amounts of acetonitrile in water (0.1% TFA). The 
coloured fractions were then further purified by semi-preparative HPLC. Lyophilisation 
yielded 5ROX-ACP3[7azaW] as a pink solid in 30.6% yield. It was found that it was 
essential to keep the reaction time short, as prolonged reaction times led to 
disappearance of the first-formed peptide product and generation of multiple species 
(Figure 5.3.)  
 
 
Scheme 5.1. Synthesis of 5ROX-ACP3[7azaW]. Reagents and conditions: a. 5ROX-SE, NaHCO3, 




































































Figure 5.3. HPLC results from the reaction of 5-ROX with ACP3[7azaW]. A) 5-ROX. B) The reaction 
mixture immediately after mixing. C) The reaction mixture after 1 h. 
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5.5 Absorbance and fluorescence of 5ROX-ACP3[7azaW] 
 
As the peptide was doubly labelled with two different fluorophores, it was necessary to 
check that the presence of the large rhodamine moiety did not hinder heme binding to 
the peptide. The absorbance profile of 5ROX-ACP3[7azaW] shows a major absorption 
peak with a maximum at 586 nm representing the rhodamine dye. However, the 
fluorescence profile shows that fluorescence at around 400 nm is much reduced upon 
excitation at 290 nm (Figure 5.4). The fluorescence of the 7-azatryptophan in the 
unmodified CP3[7azaW] is shown in blue for comparison. As there was no observed 
fluorescence around 400 nm where the Soret absorption of heme is located, this 
means it would be impossible to follow heme binding to this peptide by fluorescence 
quenching. 
 





























Figure 5.4. Absorbance (red) and fluorescence (green) spectroscopy of 5ROX-ACP3[7azaW] with 




5-ROX was chosen as a second fluorophore as its peak excitation and emission 
wavelengths appeared to be independent of those of 7-azaTrp and heme and were also 
compatible with fluorescence microscopy laser lines. However,  
Figure 5.4. shows that the doubly labelled peptide also has a small absorbance peak at 
373 nm, associated with 5-ROX, and it is therefore possible that this is the origin of the 
quenching of the 7-azaTrp fluorescence.  
 
5.6 Uptake of 5ROX-ACP3[7azaW] in FEK4 cells 
 
Although no longer suitable for use as a heme sensor, the doubly labelled peptide could 
still be used to test whether such a conjugate was cell-permeable. To do this, the peptide 
was incubated with FEK4 skin fibroblasts and the cells were then imaged by fluorescence 
microscopy. Cells were grown on glass coverslips for four days before washing with PBS 
and incubation with 1 µM or 10 µM 5ROX-ACP3[7azaW] in media or PBS for 30 or 60 
min. Cells were then washed again to remove any peptide remaining in the solution and 
fixed with paraformaldehyde. The cells were then incubated with the nuclear stain DAPI 
and mounted on glass slides with mounting media before being left to dry overnight and 
then imaged by fluorescence microscopy (Figure 5.5). 
 
The rhodamine dye should be seen in the red channel and at the 10 µM concentration, 
the peptide can be seen in cells (Figure 5.5.). However, the uptake is very uneven and 
particulate and the fluorescence is not very bright suggesting that uptake of the peptide 
is not very efficient. There is apparently very little difference between the uptake in 
media and the uptake in PBS. These results confirmed the need for additional 
development of the lead sensor peptide in order to obtain effective cell uptake.  
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Figure 5.5. FEK4 cells were incubated with 5ROX-ACP3[7azaW] (1 μM or 10 μM) for 30 or 60 min 
in media or PBS for comparison with untreated cells. Cells were then fixed and stained with DAPI. 
Images were taken with a Zeiss LSM510Meta confocal laser scanning microscope. 
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5.7 Synthesis of RRRRRRR[Ahx]ACP3[7azaW] 
 
In order to try to increase the efficiency of uptake of the peptide, a cell-penetrating 
peptide sequence was incorporated next to the hemin binding sequence on the N-
terminal side. As Förster energy transfer and therefore any fluorescence quenching is 
dependent on distance as well as overlap between emission and excitation profiles, it 
was anticipated this would also have the benefit of increasing the distance between the 
5-ROX label and the 7-azaTrp residue. Increasing the distance between the two 
fluorophores could thus relieve the unwanted quenching effect (Selvin 1995).  
Two of the most commonly used CPP sequences are the Tat sequence and a sequence 
of multiple arginine residues. However, given the Tat sequence contains multiple lysine 
residues, these would again provide alternative sites for labelling with a second 
fluorescent dye. To avoid this complication, a hepta-arginine sequence was chosen 
instead with 6-aminohexanoic acid used as a spacer between the arginines and the 
heme-binding sequence as has been  previously described (González-Magaldi et al. 
2015).  
The peptide sequence was synthesised as previously giving RRRRRRR[Ahx]ACP3[7azaW] 
as white solid in 24% yield after lyophilisation (Scheme 5.2.).
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Scheme 5.2. Synthesis of RRRRRRR[Ahx]ACP3[7azaW]. Reagents and conditions: a. Piperidine/DMF (1:4 v/v), 2 + 5 min b. Fmoc-Gly-OH, 
DIEA, PyBOP, DMF, RT, 1 h; c. Piperidine/DMF (1:4 v/v), 5 + 10 min; d. Fmoc-amino acid, PyBOP, DIEA, DMF; e. TFA/TIS/H2O/EDT 






































































































































































Repeat c and d (×7), c
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5.8 Conjugation of 5-carboxy-X-rhodamine to the N-terminus of 
RRRRRRR[Ahx]ACP3[7azaW] 
 
Once the peptide had been synthesised with the inclusion of a cell-penetrating 
sequence, a dye could again be conjugated to follow the uptake of peptide into cells. The 
same 5-ROX dye was used as previously along with the same reaction conditions.  
 
RRRRRRR[Ahx]ACP3[7azaW] (2 eq) was incubated with 5-ROX-SE in NaHCO3 pH 8.3 at 
room temperature, protected from light. The reaction was monitored by HPLC which 
again showed disappearance of the starting material and appearance of a new species 
almost immediately upon mixing. The crude product was isolated by solid phase 
extraction and HPLC as before, giving the desired labelled peptide as a pink solid albeit 
in low yield (5.3%) (Scheme 5.3). As with synthesis of 5-ROX-ACP3[7aW], it was found 
that it was essential to keep the reaction time short, since again prolonged reaction 
times led to disappearance of the first-formed peptide product and generation of 






























































































































































Figure 5.6. HPLC results from the reaction of 5-ROX with RRRRRRR[Ahx]ACP3[7azaW]. A) 5-ROX. 
B) The reaction mixture immediately after mixing. C) The reaction mixture after 1 h. 
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5.9 Absorbance and fluorescence of 5-ROX-RRRRRRR[Ahx]ACP3[7azaW] 
 
With the new labelled peptide in hand, its spectroscopic properties could again be 
investigated. It was hoped that increasing the distance between the N-terminal dye 
and the 7-azaTrp would prevent any possible quenching occurring between the two 
fluorophores. If this was successful, then the fluorescence of the 7-azaTrp should 
again be seen as a peak around 400 nm in the fluorescence spectrum of the peptide.  
However, the absorbance and fluorescence profiles of 5-ROX-
RRRRRRR[Ahx]ACP3[7azaW] were very similar to 5-ROX-ACP3[7azaW] and the 7-
azaTrp fluorescence band could not be observed (Figure 5.7.). This means that 
increasing the distance between the two fluorophores had apparently not reduced 
the quenching of the 7-azaTrp fluorescence, so making this doubly labelled peptide 
































Figure 5.7. Absorbance (red) and fluorescence (green) spectroscopy of 5-ROX-
RRRRRRR[Ahx]ACP3[7azaW] with fluorescence of CP3[7azaW] (blue), 10 μM in 10 mM 





5.10 Tandem mass spectrometry to investigate site of 5-ROX conjugation 
 
Another possible explanation for the properties of the doubly labelled peptide above 
was that the rhodamine dye had been conjugated to the sulfur of the cysteine rather 
than the N-terminal amino function of the peptide. This would mean that the 
rhodamine dye was in much closer proximity to the 7-azaTrp fluorophore than 
expected and could explain why the fluorescence of the 7-azaTrp residue was 
apparently reduced by 5-ROX. The site of conjugation would be very challenging to 
confirm by NMR spectroscopy, and is impossible to determine by normal mass 
spectrometry. However, tandem mass spectrometry (MS/MS) could be used to 
fragment the peptide and then characterise various fragments to identify which 
residue the dye might be conjugated to. 
 
5-ROX-ACP3[7azaW] was chosen for this study as its shorter sequence compared to 
5-ROX-RRRRRRR[Ahx]ACP3[7zazW] was expected to make the analysis of the 
fragments easier. In the event, the results obtained were inconclusive, as no peptide 
fragment could be identified containing the 5-ROX fluorophore without the Cys 
residue. Although a fragment consisting of the ECP[7azaW]L sequence could be 
identified without 5-ROX attached to the Cys, this does not rule out the possibility 
that the dye was removed from the Cys residue during the fragmentation, and so 
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5.11 Uptake of 5-ROX-RRRRRRR[Ahx]ACP3[7azaW] in FEK4 cells 
 
Although the longer peptide still could not be used to measure fluorescence 
quenching on heme binding, it could be used to test whether incorporation of the 
hepta-arginine sequence improved cellular uptake of the heme-binding peptide. 
Cells were treated as previously and grown on glass coverslips for four days before 
washing with PBS and incubation with 1 µM or 10 µM 5-ROX-
RRRRRRR[Ahx]ACP3[7azaW] in media or PBS for 30 or 60 min. Cells were then 
washed again to remove any peptide remaining in the solution and fixed with 
paraformaldehyde. The cells were then incubated with the nuclear stain, DAPI and 
mounted on glass slides with mounting media before being left to dry overnight. The 
cells were then imaged with fluorescence microscopy as previously (Figure 5.8.). 
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Figure 5.8.  FEK4 cells were incubated with 5-ROX-RRRRRRR[Ahx]ACP3[7azaW] (1 μM or 10 
μM) for 30 or 60 min in media or PBS for comparison with untreated cells. Cells were then 





Again, very little uptake was seen with 1 µM of peptide after 30 min. Slight red 
staining could be seen with 1 µM peptide incubated for 60 min. With 10 µM peptide, 
the cells were bright red after both 30 min and 60 min incubation. The whole cell 
appeared to be red, suggesting that the peptide may be entering many cellular 
compartments. The cells were much brighter red after incubation with 5-ROX-
RRRRRRR[Ahx]ACP3[7azaW] compared to 5-ROX-ACP3[7azaW] proving that the 





The original CP3 peptide can in principle be used to measure heme in cell lysates. 
Although only one repeat is presented here, the results are promising as the trends 
are as expected, and it also supports the hypothesis that UVA irradiation increases 
cellular free heme levels. This work in cell lysates highlights the potential of the 
peptide to be used as a heme sensor after further development to make it useable 
intracellularly. 
 
To be used in cells, the peptide should interfere with the cellular machinery as little 
as possible. The MTT assay was used to establish that the lead heme-binding peptide 
does not interfere with mitochondrial function and showed that the peptide is 
virtually non-toxic to FEK4 cells. 
 
The next challenge to develop the sensor for intracellular use was to ensure that it 
can enter live cells. As the fluorescence of the 7-azaTrp is in the near UV-region, it is 
not detectable by many fluorescence microscopes. A secondary fluorophore was 
therefore needed to image the peptide in cells and assess its uptake. The rhodamine 
dye, 5-ROX was conjugated to the peptide, which was then incubated with live FEK4 
cells. A small amount of fluorescence was then seen in the cells, but the uptake was 
139 
 
inconsistent and not every cell became fluorescent. Therefore, a longer peptide was 
synthesised that included a cell-penetrating peptide sequence fused to the heme-
binding peptide sequence. The same rhodamine dye was then conjugated to the 
longer peptide and it was tested for cell uptake. The fluorescence of this peptide was 
much stronger in cells and seemed to cover nearly the whole cell. Therefore, it could 
be concluded that the inclusion of the cell-penetrating sequence is highly beneficial 
for promoting uptake of the peptide by FEK4 cells and should be included during 
further development. 
 
In order to properly quantify the levels of heme in cells, the amount of peptide that 
has entered the cell needs to be quantifiable. The fluorescence signal of 7-azaTrp 
would not be suitable for this application because it can be quenched by any heme 
present and would therefore give a readout lower than that corresponding to the 
actual amount of peptide present. For this work therefore a second, independent 
fluorophore was necessary whose fluorescence could be reliably related back to 
peptide concentration. 5-X-carboxyrhodamine was expected to be a good choice for 
an independent dye as its excitation wavelength is 586 nm, which is further in the 
red part of the spectra than heme and so should not interfere spectroscopically with 
any heme measurement. However, when conjugated to the peptide, the previously 
observed fluorescence of the CP3[7azaW] peptide around 400 nm that was 
attributed to the 7-azaTrp residue had been drastically reduced.  Unfortunately, this 
made the peptide in this form unsuitable for use as a heme sensor. 
 
The quenching of the fluorescence of 7-azaTrp was not relieved when the distance 
between this residue and the 5-X-carboxyrhodamine fluorophore was extended by 
the addition of an N-terminal cell-penetrating peptide spacer to the CP3[7azaW] 
sequence. This suggests that the choice of this pair of fluorophores is still not optimal 
and therefore other combinations should be considered. 
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A further possible explanation for the behaviour of the doubly labelled peptides is 
that the rhodamine dye was in fact conjugated to the sulfur of the Cys rather than 
the N-terminal amino function of the peptides during both labelling reactions 
performed. This would place the rhodamine dye in much closer proximity to the 7-
azaTrp fluorophore than expected, which is impossible to determine by normal mass 
spectrometry. Selective fragmentation of the shorter rhodamine-labelled peptide 
using MS/MS techniques could not fully confirm that the site of labelling was indeed 
at the N-terminus, and not at Cys, although some fragments identified were 
consistent with the desired labelling outcome. Additional support for preferential N-
terminal labelling over labelling at Cys does come from reports suggesting that good 
selectivities can be obtained when the dye is attached via a succinimidyl ester as was 
employed here, although for optimum results carrying out the reaction at pH 7.0 is 
also recommended (Bark and Hahn, 2000). As 5-ROX conjugation to the Cys would 
also completely block the main hemin binding site of the peptide sensors, UV-Vis 
titrations with hemin might also be carried out to see if hemin binding is drastically 
reduced compared to the unlabelled peptides. Even if the dye was blocking the Cys 
residue but nonspecific binding was occurring, this should be distinguishable from 
Cys-mediated binding by looking at the shape of the difference spectra (see Chapter 
3). Lastly, another method to test the site of the dye labelling would be to simply 
react the peptide with iodoacetamide. Iodoacetamide is an alkylating agent that 
reacts preferentially with thiol groups, so if the side chain thiol of Cys remained free 
(i.e. as for the desired N-terminally labelled peptides), it would be derivatised and 
the corresponding increase in molecular weight could be demonstrated by mass 
spectrometry.  
 
In summary, while the unlabelled CP3[7azaW] peptide does shows promise as a 
heme sensor for use in biological systems, further development is still needed to 
















Bach1 is a negative regulator of transcription that can sense heme and has an 
important role in heme homeostasis through the regulation of several proteins 
involved in heme homeostasis (Zhou et al. 2016). Bach1 plays a key role in the cellular 
response to oxidative stress by allowing induction of HO-1 which can catabolise pro-
oxidative heme and release the antioxidants CO and biliverdin. Given the 
involvement of heme, Bach1 and HO-1 in a number of diseases involving components 
of oxidative stress (Abraham and Kappas 2008), HO-1 is emerging as a target for 
therapeutic intervention and drug discovery (Motterlini and Foresti 2013). However, 
much of the effort in this area so far has gone into inducing Nrf2 with much less 
attention paid to Bach1, perhaps because there is still much to understand about the 
role of heme, Bach1 and HO-1 in human pathophysiology.   
This chapter aimed to use recombinant DNA to express human Bach1 protein. The 
purpose of this was two-fold. Firstly, for the further development of the heme-
binding peptides produced in the previous chapters, and secondly, for investigations 
on the targeting of Bach1 with other heme-like porphyrins and hence modulation of 
its DNA-binding activity. Competition assays were designed to test the interaction 
between a heme-binding peptide in the presence of Bach1, and it was envisaged that 
electrophoretic mobility band shift assays (EMSA) could be used to investigate the 
binding of Bach1 to DNA in the presence of hemin and a heme-binding peptide. 
Further, the ability of different heme-like porhyrins to affect the DNA-binding activity 
of Bach1 could also be tested by EMSA. As there is no crystal structure of full length 
Bach1, purified protein could potentially be used further for crystallisation studies 
and detailed structural investigations. 
There have been several previous reports on the expression and DNA-binding 
properties of mammalian Bach1 proteins. Recombinant mouse Bach1 has been 
previously expressed as a GST fusion protein in E. coli and purified with a glutathione 
labelled Sepharose column (Ogawa et al. 2001). The protein that was produced was 
used for EMSAs. Human His-tagged Bach1 has been expressed in E. coli and purified 
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with Ni-NTA resin (Hintze et al. 2007), and once again the purified protein was probed 
in EMSA studies to confirm Bach1-DNA promoter interaction. The BTB domain of the 
mouse Bach1 has also been expressed with a His-tag in E. coli and purified by nickel 
affinity chromatography for crystallisation and structure determination (Ito et al. 
2009). Finally, Bach1 with a FLAG tag in a baculovirus vector was used to express the 
construct in High Five insect cells  (Cantor et al. 2004). The Bach1-FLAG was then 
purified by FLAG affinity resin and tested for its enzymatic activity. 
 
Given the complex structure of Bach1 and the presence of several heme prosthetic 
groups, a human expression system was chosen for this project, in order to achieve 
correct post-translational processing and quaternary structure of the expressed 
protein. To this end, chose a system from a recent report on a suspension cell system 
composed of human embryonic kidney cells (HEK 293-F) that described the 





A plasmid expressing a Bach1-GFP fusion construct was derived in this laboratory 
(Figure 6.1) (Raval et al. 2012) and a plasmid expressing a Bach1-FLAG tagged 




Figure 6.1. Map of the pEGFP-N1 vector. The Bach1 gene was inserted into the MCS (multiple 
cloning site) region using EcoR1 and Kpn1. 
 
 
Figure 6.2. Map of the pFLAG-CMV vector. The Bach1 gene was inserted into the MCS region 
using EcoR1 and Sal1. 
 
6.3 Transfection of HEK 293-F cells with Bach1-GFP 
 
In order to test the transfection efficiency, a test transfection was carried out with 
the Bach1-GFP plasmid so that transfection could be monitored by detection of the 
fluorescence of the GFP of the Bach1-GFP construct. Transfection was carried out by 
the protocol of Portolano et al., 2014, using polyethylenimine (PEI) as the 
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transfection reagent. Expression of GFP was observed and transfection efficiency was 
calculated to be 53% (Figure 6.3.).  
 
Bright Field 405 nm 488 nm Merge 
    
Figure 6.3. Transfection of HEK 293-F cells with Bach1-GFP. Cells were transfected with the 
Bach1-GFP encoding plasmid and incubated at 37 °C for 48 h to allow for protein production. 
Cells were then harvested, fixed and stained with DAPI adhered to glass coverslips by 
centrifugation, and imaged by fluorescence microscopy. 
 
6.4 Transfection of HEK 293-F cells with Bach1-FLAG 
 
The FLAG tag is a polypeptide sequence of DYKDDDDK that can be used in affinity 
chromatography to purify tagged proteins from non-tagged proteins (Hopp et al. 
1988). The same transfection procedure as described above was therefore now used 
with the non-fluorescent but FLAG-tagged Bach1 encoding plasmid, and purification 
was also carried out according to the protocol of Portolano et al., 2014, using anti-
FLAG M2 antibody labelled affinity gel. Cells were lysed and large molecular debris 
(e.g. membranes and DNA complexes) were removed by centrifugation. The 
supernatant was then incubated with the affinity gel. The protein was then cleaved 
from the resin using enterokinase overnight at 4 °C. Enterokinase cleaves after a 
DDDDK amino acid sequence which is part of the FLAG-tag. Any further bound 
protein was then eluted from the resin using glycine HCl, pH 3.0. Samples were 
collected from each stage of the procedure for analysis by SDS-PAGE and Coomassie 
Blue protein staining. 
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The whole cell lysate obtained showed an abundant protein species at around 72 kDa 
on SDS-PAGE analysis with Coomassie Blue staining. Although the expected 
molecular weight for Bach1 is 82 kDa, the transfected plasmid should lead to 
overexpression of the protein and as this was the most abundant gel band it is 
possible that it does indeed represent Bach1 (Figure 6.4. 8.). However, after 
incubation of the lysate with the affinity gel and then washing with buffer to remove 
unbound protein, no protein bands were seen (Figure 6.4 3.). This would suggest that 
there was no protein binding to the gel. Further purification steps still did not show 
the presence of any protein (Figure 6.4 4-6, 11-12.). Based on these results, it is 
difficult to determine if the failure to isolate any protein resulted from the 
























































































































































































































6.5 Western Blotting of cell lysate with anti-FLAG antibody 
 
In order to investigate whether Bach1-FLAG was expressed in the cells and where it 
should run on the SDS-PAGE, Western blotting with an anti-FLAG antibody was 
performed on the cell lysate. The anti-FLAG antibody chosen was the same clone as 
that conjugated to the affinity gel used for purification so that comparisons could be 
made between the two results (Clone M2, Sigma). After transfection, harvest and 
lysis as described previously, the lysate was subjected to SDS-PAGE, followed by 
transfer to nitrocellulose membrane.  Primary antibody staining with the M2 anti-
FLAG antibody raised in mouse was followed by secondary antibody staining with a 
fluorescent anti-mouse antibody (LI-COR). The membrane was then imaged with an 




























Figure 6.5. Western blotting of HEK 293F cell lysate with anti-FLAG antibody. A Coomassie 
stain of the same sample is included for comparison. 
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The Western blot in Figure 6.5. shows the absence of any FLAG epitope from the cell 
lysate. The band at 72 kDa seen on the Coomassie stain therefore does not seem to 
represent the Bach1-FLAG construct. One possibility is that during cell lysis the 
Bach1-FLAG construct is fragmented; as Bach1 consists of several domains it could 
be particularly susceptible to lysis during sonication. If the FLAG tag was lost from the 
protein, this would explain why the protein cannot be purified using the anti-FLAG 
affinity gel and why no bands were observed on the Western blot. This could also 
help explain why the principal band on the gel appears at a position on the gel 
corresponding to a size 10 kDa lower than the size of the expected protein. 
 
6.6 Mass spectrometry of the proteins in the 72 kDa-running SDS-PAGE band 
 
To complement the Western blotting results and further investigate the most highly 
abundant protein seen in the SDS-PAGE, mass spectrometry was employed to 
investigate the identity of the protein. The band from the gel was excised and 
subjected to a trypsin digest (carried out by Christopher Vennard, University of Bath) 
before mass spectrometry analysis (by the MS/MS method). Peptide fragments were 
identified by Mascot v2.4.1 (Matrix Science) using the SwissProt database. Even if the 
72 kDa band contained a truncated version of Bach1, fragments from the trypsin 
digest could still be used to identify the protein. Table 6.1 shows the proteins 












It was not possible to express and purify human Bach1 given the time constraints of 
this project. Transfection and expression of the Bach1-GFP fusion appears to have 
been successful, suggesting that that transfection protocol chosen was suitable. 
However, this does not guarantee that the transfection of the Bach1-FLAG was 
successful as the plasmids and constructs are not exactly the same. Further 
investigation, such as immunostaining of whole cells with antibodies against the 
FLAG tag and against Bach1 could help confirm whether the plasmid is successfully 
transfected and expressed in intact cells. If this proved unsuccessful, then the 
transfection protocol itself could be optimised or different expression systems 
tested. If the expression is confirmed, then this would indicate that optimisation of 
the purification protocol is needed instead, or a different protein tag should be 
investigated.  
  
Accession Mass (Da) Description 
HS71A_HUMAN 70294 
Heat shock 70 kDa protein 1A OS=Homo sapiens 
GN=HSPA1A PE=1 SV=1 
K2C1_HUMAN 66170 
Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 
K1C9_HUMAN 62255 
Keratin, type I cytoskeletal 9 OS=Homo sapiens 
GN=KRT9 PE=1 SV=3 
HS90B_HUMAN 83554 
Heat shock protein HSP 90-beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 
K1C10_HUMAN 59020 
Keratin, type I cytoskeletal 10 OS=Homo sapiens 

















In Chapter 3 of this thesis the construction of a prototype heme sensor with the 
peptide sequence ARSECP[7azaW]LG has been described. The sensor relies on the 
fluorescence of 7-azatryptophan which is quenched in proportion to the amount of 
hemin present. The peptide was derived from one of the heme-binding motifs of the 
transcriptional regulator protein, Bach1. 
Traditionally, cellular heme has been measured by spectroscopic methods after 
treatment of tissue by a variety of chemical steps. One method involves 
homogenising cell or tissue samples and reducing and treating the resultant lysates 
with pyridine in alkali so that the nitrogen ligands from protein-bound heme are 
replaced by pyridine so that the pyridine hemochromogen can be detected by 
absorbance spectroscopy (Paul et al. 1953). Alternatively homogenised cell or tissue 
samples were heated and acidified to release heme from hemoproteins and remove 
the iron to convert the heme into PPIX. The fluorescence of PPIX was then measured 
and assumed to equal the concentration of heme (Morrison 1965). A third method 
involves extracting heme from cells or tissues with acetone and HCl and then 
analysing the species present by HPLC (Sinclair et al. 2001). None of these methods 
are able to distinguish free heme from protein bound heme nor are they sensitive 
enough to recognise the very low levels of free heme in the cell. The peptide-probe 
heme-sensors developed here can in principle be used without any pre-treatment of 
cells to measure free heme levels or after treatment of cells to remove heme from 
hemoproteins.  
The fact the sensors developed in this work rely on quenching of fluorescence is not 
ideal as quantifying the reduction of fluorescence with increasing hemin makes it 
more difficult to determine exactly when the sensor is fully saturated than if they 
were a ‘turn on’ sensor where fluorescence would increase with increasing hemin 
concentration (Zhang et al. 2014). However, none of the previously designed sensors 
for heme have overcome this flaw. While it is a promising tool for measurement of 
heme levels in biological samples ex vivo, the basic sensor developed here cannot be 
used in live cells to quantify heme concentration as there would be no way to correct 
the reading for the concentration of peptide that entered the cell. This is because it 
is not possible to independently excite the 7-aatryptophan without its emission being 
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quenched by any cellular hemin. A heme sensor using a fusion protein of enhanced 
green fluorescent protein (EGFP) and the heme binding protein apocytochrome b562 
also suffered from this problem and could only be used to monitor the fluorescence 
quenching of EGFP when heme binds to apocytochrome b562 (Takeda et al. 2003). 
More recently, the heme sensor constructed by Koga et al. based on the heme 
binding protein heme oxygenase-1 and small molecule fluorophores is also ultimately 
limited to simple use in a cell-free system (Koga et al. 2013; Taira et al. 2015). In order 
to quantify the concentration of heme intracellularly therefore, the sensor needs to 
be ratiometric, or contain an internal standard of fluorescence. Further development 
of this work in Chapter 5 aimed to address this challenge. 
 
In Chapter 4, the creation of further heme-binding peptides, HXNP1 and HXNP2 that 
were expected to have higher affinities for hemin was described. These were inspired 
by the 3D structure of the heme-binding site of hemopexin, a protein with the highest 
known affinity for heme. Development of these peptides into heme sensors was 
attractive as it could have aided further investigation of the very low (nM-pM) 
concentrations of free heme that may be present in different organelles. However, 
difficulties were encountered elucidating the heme-binding stoichiometries and thus 
quantifying binding affinities of these peptides for hemin, and so this area of work 
was suspended in favour of the Bach1-derived peptide probes.  
 
Chapter 5 extended the work in Chapter 3 with the aim of attaching an independent 
fluorophore that could be used to monitor the uptake of the previous peptide sensor 
in cells. While conjugation of 5-carboxy-X-rhodamine to the N-terminus of CP 
peptides did allow for testing of the uptake of such a heme-binding peptide in cells, 
it also interfered with the fluorescence of the 7-azatryptophan residue, thereby 
nullifying the peptide’s suitability for use as a heme sensor.  However, the shorter 
CP3[7azaW] peptide was used in cell lysates to reveal an increase in heme levels after 
UVA irradiation of FEK4 cells compared to untreated cells. 
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Some elegant solutions have recently been devised to address the challenge of 
producing a heme sensor with a quantifiable level in cells. Song et al. created a 
protein-based ratiometric heme sensor that relied on the binding of heme between 
two heme-binding protein domains (IsdX1 and IsdC) that were each attached to a 
fluorescent protein (enhanced cyan fluorescent protein (ECFP) and enhanced yellow 
fluorescent protein (EYFP)). Heme binding brought the domains together causing 
energy transfer between the fluorescent domains (Song et al. 2015).  This construct 
was encoded into plasmids which were transfected into HeLa cells and used to 
monitor the increase in cellular heme after treatment of cells with 5 µM exogenous 
hemin. 
Hanna et al. recently developed a genetically encoded heme sensor that is again 
based on the quenching of the fluorescent protein EGFP by heme binding to 
cytochrome b562 but also has another fluorescent protein, Katushka 2 (mKATE2) that 
exhibits heme-insensitive fluorescence (Hanna et al. 2016). The red fluorescence of 
mKATE2 is not affected by heme binding and therefore can be used to normalise the 
altered fluorescence of EGFP upon heme binding. The spectral properties of mKATE2 
(excitation = 588 nm, emission = 620 nm) are very similar to that of 5-ROX used here, 
indicating that our basic design strategy in Chapter 5 is sound. 
 
However, a small molecule sensor has significant advantages over a genetically 
encoded sensor. It does not need to be transfected into a cell using plasmids or stably 
incorporated into the genome. Neither of these processes are facile. For preliminary 
testing of a sensor produced in this way, the expressed protein needs to be purified 
from the cell which is time consuming and expensive and can give very low yields. 
Chemical synthesis and purification of a short modified peptide is often much more 
simple to carry out. A small molecule also overcomes the risk of interfering with the 
normal physiological heme metabolism of the cell that comes from constitutively 
expressing extra heme-binding proteins. A small molecule sensor as designed here 
does not rely on conformational change between large protein domains and two 
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fluorophores, but only the direct energy transfer between the substrate heme and 
the fluorophore providing the readout. 
 
Further development of the Bach1-inspired peptide probe developed in this project 
is needed to make it functional in cells. Further optimisation could be carried out on 
all aspects of the sensor – the heme binding sequence, the fluorophores or even the 
linker between the two. 
The heme concentration of the cytosol of Saccharomyces cerevisiae has been 
previously reported as in the nM range using a sensor with a Kd for hemin of 0.5–2.0 
μM (Hanna et al. 2016). This Kd range is very similar to the range for the heme-binding 
peptides tested here. However, the concentration in the mitochondria and nucleus 
was estimated to be lower than 2.5 nM using a sensor with a Kd for hemin of 3 nM. 
Therefore, if the peptide based heme sensors from this work were to be employed 
for measuring heme concentration in subcellular organelles, further development of 
the heme-binding sequence would be necessary. This could involve further 
development of the HXNP peptides as discussed in Chapter 4 as currently, the 
sequences of peptides capable of binding heme through His or Tyr has not been 
studied to the same extent as Cys-containing peptides (Kühl et al. 2011; Kühl et al. 
2013). Alternatively, the information gained from the sequence analysis of Cys-
containing peptides could be combined with the information gained here to design a 
CP peptide with specific properties rather than basing one on the sequence of a 
natural heme-binding protein alone. 
In order to measure heme concentration in specific organelles, variations of the 
peptide to incorporate subcellular targeting peptide sequences would also need to 
be considered. Mitochondria-penetrating peptides with the sequence FXrFXKFXrFXK 
(Fx = cyclohexylalanine, r = d-Arg) can be used to target cargo to the mitochondria 
(Horton et al. 2008). There are also a number of nuclear localisation sequences 
derived from nuclear-targeted protein sequences such as GRKKRRQRRRPPQC, 




In terms of optimising the fluorophores, an alternative azatryptophan could be 
incorporated. For example, 4-azatryptophan has a higher fluorescence intensity 
compared to 7-azatryptophan and a 65 nm greater red-shift than 7-azaTrp (Lepthien 
et al. 2008). Methylation of azatryptophans can also alter their spectroscopic 
properties in a beneficial fashion. 1-Methyl-7-azatryptophan and 1,7-dimethyl-7-
azatryptophan both display greater red-shifted fluorescence than 7-azatryptophan 
(Noichl et al. 2015) as do 1-methyl-4-azaindole and 1,4-dimethyl-4-azaindole (Merkel 
et al. 2010). None of these potential Trp analogues are currently available 
commercially in Fmoc protected form but could be chemically synthesised. A greater 
red-shifted fluorescence could potentially avoid overlap of emission of these 
fluorophores with the 373 nm absorbance peak of 5-ROX. Additionally, a different 
independent fluorophore could be coupled to the N-terminus of the peptide such as 
AlexaFluor633, Cy5 or Texas Red. Another possibility for optimisation is to increase 
the length of the linker between the heme-binding and heme-sensitive fluorophore 
and the secondary fluorophore. 
 
When these issues have been addressed, the sensor could be employed in cells in a 
similar way to the Cytb562-EGFP-mKATE2 employed in Saccharomyces cerevisiae by 
Hanna et al. (2016) but without the need for the host cell to be expressing the protein 
sensor. A combination of fluorimetry, flow cytometry and fluorescence microscopy 
was used to determine the cellular heme concentration in Hanna et al.’s work and a 
small molecule sensor should also be suitable to use in all three methods.  
 
The work in this thesis aimed to develop for the first time a small-molecule heme 
sensor that could be applied to any cell type or biological sample to investigate heme 
levels after a variety of treatments. Of particular interest here was the effect of UVA 
irradiation on heme levels. The prototype probe KRSECP[7azaW]LG  was used to 
investigate heme levels in skin cell lysates after treatment with UVA irradiation. 
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Although only preliminary data is presented here, the trends in the data – an increase 
in F0-F in the control cell sample compared to the total fluorescence of the peptide, 
with further increases after pre-loading the cell with exogenous hemin (10 µM) and 
irradiation with UVA irradiation (250 kJ/m2) – are promising. The increase in F0-F 
suggests that free heme levels are increased after UVA irradiation which agrees with 
previous reports on the effect of UVA on skin cells (Kvam et al. 1999). Further 
investigation into this area should involve a dose response curve to correlate the 
levels of heme with increasing doses of UVA irradiation and to investigate what 
happens to heme levels at different time points after UVA irradiation. As 250 kJ/m2 
is only a moderate dose – equivalent to about an hour of sun exposure at midday in 
Southern Europe – increases in UVA dose could cause further increases in heme 
which could be used to further test the peptide sensor. 
 
Another potential use for the heme-binding peptides developed here would be as 
tools for investigations into the action of Bach1. Bach1 is ordinarily bound to the 
promoter of HO-1 and prevents transcription, however, when heme binds to the Cys-
Pro motifs of Bach1, the transcription factor is released from the DNA. If the 
dissociation constant of the peptide was as low as the dissociation constant of Bach1 
for heme then the peptide would be able to compete with Bach1 for free heme.  This 
would prevent the release of Bach1 from DNA and the transcription of HO-1, allowing 
investigation of the dependence of downstream processes on Bach1 or HO-1 activity. 
Another possibility would be to use the peptide to deliver other ‘heme-like 
porphyrins’ into the nucleus that are capable of modulating the DNA binding ability 
of Bach1, either positively or negatively. Further optimisation of the current heme-
binding peptides as suggested above should allow some of these interesting 
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A.1 Fitting Absorbance data 
 
A.1.1 CP3 Repeat 1 397 nm
 
Calculated εΔHG  -14028.4 
Calculated Ka 1.87428e+07 
Sum of squares (ss) 0.00288177 
Standard error (SEy) 0.0143471 
Covariance of fit 0.0588962 
 
A.1.2 CP3 Repeat 2 397 nm 
 
Calculated εΔHG  -14313.8 
Calculated Ka 293330 
Sum of squares (ss) 0.00072665 
Standard error (SEy) 0.00720441 




A.1.3 CP3 Repeat 3 397 nm 
 
Calculated εΔHG  -14080 
Calculated Ka 587136 
Sum of squares (ss) 0.000591979 
Standard error (SEy) 0.00650263 
Covariance of fit 0.0171582 
 
A.1.4 CP4 Repeat 1 367 nm 
 
Calculated εΔHG  68297.8 
Calculated Ka 29194.5 
Sum of squares (ss) 0.0167935 
Standard error (SEy) 0.0359417 





A.1.5 CP4 Repeat 2 367 nm 
 
Calculated εΔHG  122482 
Calculated Ka 18422.5 
Sum of squares (ss) 0.00831339 
Standard error (SEy) 0.0243683 
Covariance of fit 0.0280931 
 
A.1.6 CP4 Repeat 3 367 nm 
 
Calculated εΔHG  57383.1 
Calculated Ka 62289.4 
Sum of squares (ss) 0.00595913 
Standard error (SEy) 0.0206313 





A.1.7 CP6 Repeat 1 368 nm 
 
Calculated εΔHG  13933.9 
Calculated Ka 4.87508e+07 
Sum of squares (ss) 0.000240768 
Standard error (SEy) 0.00447928 
Covariance of fit 0.00562466 
 
A.1.8 CP6 Repeat 2 368 nm 
 
 
Calculated εΔHG  10850.6 
Calculated Ka 2.33461e+08 
Sum of squares (ss) 0.00180657 
Standard error (SEy) 0.0113596 




A.1.9 CP6 Repeat 3 366 nm 
 
Calculated εΔHG  6841.78 
Calculated Ka 1.3352e+06 
Sum of squares (ss) 0.000891853 
Standard error (SEy) 0.00862097 
Covariance of fit 0.130684 
 
A.1.10 IRP2 Repeat 1 418 nm 
 
Calculated εΔHG  20372.8 
Calculated Ka 79763.8 
Sum of squares (ss) 5.4252e-05 
Standard error (SEy) 0.00196854 





A.1.11 IRP2 Repeat 1 367 nm 
 
Calculated εΔHG  22971.4 
Calculated Ka 2.94433e+06 
Sum of squares (ss) 0.0013028 
Standard error (SEy) 0.00964661 
Covariance of fit 0.00998985 
 
A.1.12 IRP2 Repeat 2 418 nm 
 
Calculated εΔHG  31898.4 
Calculated Ka 51348.7 
Sum of squares (ss) 6.78631e-05 
Standard error (SEy) 0.00220167 





A.1.13 IRP2 Repeat 2 367 nm 
 
Calculated εΔHG  21405.5 
Calculated Ka 1.58833e+06 
Sum of squares (ss) 0.00130578 
Standard error (SEy) 0.00965764 
Covariance of fit 0.0125627 
 
A.1.14 IRP2 Repeat 3 418 nm 
 
Calculated εΔHG  35636 
Calculated Ka 35019.1 
Sum of squares (ss) 8.44768e-05 
Standard error (SEy) 0.00254916 





A.1.15 IRP2 Repeat 3 367 nm 
 
Calculated εΔHG  19137.8 
Calculated Ka 1.12051e+06 
Sum of squares (ss) 0.00095599 
Standard error (SEy) 0.00857541 






A.2 Fitting fluorescence data 
 
A.2.1 CP3 Repeat 1 357.5 nm 
 
Calculated εΔHG  8.20353e+07 
Calculated Ka 5.03416e+06 
Sum of squares (ss) 120352 
Standard error (SEy) 92.7176 
Covariance of fit 0.0768804 
 
A.2.2 CP3 Repeat 2 356 nm 
 
Calculated εΔHG  7.7148e+07 
Calculated Ka 1.34043e+06 
Sum of squares (ss) 47561.4 
Standard error (SEy) 58.2859 
Covariance of fit 0.0358403 
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A.2.3 CP3 Repeat 3 356 nm 
 
Calculated εΔHG  7.88612e+07 
Calculated Ka 2.07984e+06 
Sum of squares (ss) 144389 
Standard error (SEy) 101.556 
Covariance of fit 0.116372 
 
A.2.4 CP3 Repeat 4 355.5 nm 
 
Calculated εΔHG  5.91233e+07 
Calculated Ka 2.82463e+06 
Sum of squares (ss) 11008.4 
Standard error (SEy) 28.0413 





A.2.5 CP3[7azaW] Repeat 1 402 nm 
 
Calculated εΔHG  8.68975e+07 
Calculated Ka 1.14835e+06 
Sum of squares (ss) 86944.8 
Standard error (SEy) 78.8057 
Covariance of fit 0.055623 
 
A.2.6 CP3[7azaW] Repeat 2 401.5 nm 
 
Calculated εΔHG  7.24035e+07 
Calculated Ka 4.13077e+06 
Sum of squares (ss) 108585 
Standard error (SEy) 91.3929 





A.2.7 CP3[7azaW] Repeat 3 401 nm 
 
Calculated εΔHG  9.88311e+07 
Calculated Ka 582548 
Sum of squares (ss) 14980.3 
Standard error (SEy) 32.7112 





A.3 HXNP1 COSY NMR spectrum 
 
1H-1H COSY spectrum of a DMSO-d6 solution of HXNP1. 
